<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1310222734
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRIUMEQ 50mg/600mg/300mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOLUTEGRAVIR,LAMIVUDINE,ABACAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50,300,600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3128.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Poznan " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Poznan 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        J05AR02 
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TRIUMEQ is a medicine that contains three active substances used to treat HIV infection: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine belong to a group of anti-retroviral medicines (medicines used to treat HIV infection) called <em>nucleoside analogue reverse transcriptase inhibitors (NRTIs)</em>, and dolutegravir belongs to a group of anti-retroviral medicines called <em>integrase inhibitors (INIs)</em>.</p><p>TRIUMEQ is used to treat HIV (human immunodeficiency virus) infection in adults, adolescents and children over 12 years old who weigh at least 40 kg.</p><p>Before you are prescribed TRIUMEQ your doctor will arrange a test to find out whether you carry a particular type of gene called HLA-B*5701. TRIUMEQ should not be used in patients who are known to carry the HLA-B*5701 gene. Patients with this gene are at a high risk of developing a serious hypersensitivity (allergic) reaction if they use TRIUMEQ (see &lsquo;hypersensitivity reactions&rsquo; in section 4).</p><p>TRIUMEQ does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. It also increases the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with TRIUMEQ in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take TRIUMEQ:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_570a5ade-b8be-46f4-8efb-11f433910dcb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li>if you are <strong>allergic </strong>(<em>hypersensitive</em>)<strong> </strong>to dolutegravir, abacavir (or any other medicine containing abacavir), or lamivudine, or any of the other ingredients of this medicine (listed in section 6).</li><li><strong>Carefully read all the information about hypersensitivity reactions in Section 4</strong>.</li><li>&nbsp;If you are taking a medicine called <strong>fampridine</strong> (also known as dalfampridine; used in multiple sclerosis).</li></ul><p>&reg; If you think any of these apply to you, tell your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>IMPORTANT &mdash; Hypersensitivity reactions</strong></p><p><strong>TRIUMEQ contains abacavir and dolutegravir. </strong>Both of these active substances can cause a serious allergic reaction known as a hypersensitivity reaction. You should never take abacavir or abacavir-containing products again if you have a hypersensitivity reaction: it can be life threatening.</p><p><strong>You must carefully read all the information under &lsquo;Hypersensitivity reactions&rsquo; in the panel in Section 4</strong>.</p><p>The TRIUMEQ pack includes an <strong>Alert Card</strong> to remind you and medical staff about hypersensitivity. <strong>Detach this card and keep it with you at all times</strong>.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Take special care with</strong><strong> TRIUMEQ </strong></p><p>Some people taking TRIUMEQ or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have moderate or severe liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have ever had <strong>liver disease,</strong> including hepatitis B or C (if you have hepatitis B infection, don&rsquo;t stop TRIUMEQ without your doctor&rsquo;s advice, as your hepatitis may come back)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have a kidney problem</p><p><strong>&reg; </strong><strong>Talk to your doctor if any of these apply to you before using TRIUMEQ.</strong> You may need extra check-ups, including blood tests, while you&rsquo;re taking your medicine. See Section 4 for more information.</p><p>&nbsp;</p><p><u>Abacavir hypersensitivity reactions</u></p><p>Even patients who don&rsquo;t have the HLA-B*5701 gene may still develop a <strong>hypersensitivity reaction</strong> (a serious allergic reaction).</p><p><strong>&reg; </strong><strong>Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.</strong></p><p><strong>&nbsp;</strong></p><p><u>Risk of cardiovascular events</u></p><p>It cannot be excluded that abacavir may increase the risk of having cardiovascular events.</p><p><strong>&reg; </strong><strong>Tell your doctor </strong>if you have cardiovascular problems, if you smoke, or have other illnesses that may increase your risk of cardiovascular diseases such as high blood pressure or diabetes. Don&rsquo;t stop taking TRIUMEQ unless your doctor advises you to do so.</p><p><strong>&nbsp;</strong></p><p><u>Look out for important symptoms</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b12891ae-2735-423b-8f56-ab900e3f0960 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8570e39c-f2df-4232-a700-3ccc74e9d518 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><ul><li>symptoms of infections and inflammation</li><li>joint pain, stiffness and bone problems</li></ul><p>You need to know about important signs and symptoms to look out for while you&rsquo;re taking TRIUMEQ.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_837a3b88-3668-4715-813b-73beb3fda486 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&reg; <strong>Read the information &lsquo;Other possible side effects of combination therapy for HIV&rsquo; in Section 4 of this leaflet.</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_80d62ab0-74ad-4460-b20a-b593a38fc872 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p><strong>Children</strong></p><p>This medicine is not for children under 12 years of age. The use of TRIUMEQ in children under 12 years of age has not yet been studied.</p><p>&nbsp;</p><p><strong>Other medicines and TRIUMEQ</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Don&#39;t take Triumeq with the following medicine:</p><ul><li>&nbsp;fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li></ul><p>&nbsp;</p><p>Some medicines can affect how TRIUMEQ works or make it more likely that you will have side effects. TRIUMEQ can also affect how some other medicines work.</p><p><strong>Tell your doctor</strong> if you are taking any of the medicines <em>in the following list</em>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, to treat <strong>diabetes</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines called <strong>antacids</strong>, to treat <strong>indigestion</strong> and <strong>heartburn. Do not take an antacid </strong>during the 6 hours before you take TRIUMEQ, or for at least 2&nbsp;hours after you take it. (<em>See also Section&nbsp;3).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; supplements or multivitamins containing calcium, iron or magnesium. <strong>If you take TRIUMEQ with food, </strong>you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as TRIUMEQ. <strong>If you do not take TRIUMEQ with food, do not take supplements or multivitamins containing calcium, iron or magnesium </strong>during the 6 hours before you take TRIUMEQ, or for at least 2&nbsp;hours after you take it <em>(see also Section 3).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat <strong>HIV infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines containing lamivudine, used to treat <strong>HIV infection</strong> or <strong>hepatitis B infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cladribine, used to treat <strong>hairy cell leukaemia</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, to treat tuberculosis (TB) and other <strong>bacterial infections</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trimethoprim/sulfamethoxazole, an antibiotic to treat <strong>bacterial infections</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin and phenobarbital, to treat <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oxcarbazepine and carbamazepine, to treat <strong>epilepsy</strong> and <strong>bipolar disorder</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort</strong> (<em>Hypericum perforatum</em>), a herbal remedy to treat <strong>depression</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Methadone, </strong>used as a <strong>heroin substitute.&nbsp; </strong>Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be&nbsp;changed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Riociguat</strong>, used to treat<strong> high blood pressure in the blood vessels </strong>(the pulmonary arteries) that carry blood from the heart to the lungs. Your doctor may need to reduce your riociguat dose, as abacavir may increase riociguat blood levels.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check-ups.</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bc16b0a1-cfce-4fdc-ac4b-9ec49f5cff18 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_af7667d7-e6d6-477a-9996-7eb9a595abaf \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> Talk to your doctor </strong>about the risks and benefits of taking TRIUMEQ.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fb9523cd-676d-4004-99a1-3063b45938d4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Taking Triumeq at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a type of birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk529198760'> DOCVARIABLE
vault_nd_5132b86c-f3df-4682-a42c-e74f20e179c0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-end'></span><![endif]--></p><p>If you could get pregnant while receiving Triumeq,<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk529198760'> DOCVARIABLE
vault_nd_52ca68c5-0b24-4302-8310-2c629701b109 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-end'></span><![endif]--></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> Talk to your doctor</strong> and discuss whether there is a need for contraception, such as condom or pills.<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk529198760'><span style='mso-bidi-font-size:11.0pt;
mso-bidi-font-weight:bold'> DOCVARIABLE
vault_nd_7114adc8-42be-4852-98c0-b00e7a01f014 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk529198760'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Triumeq without consulting your doctor, as this may harm you and your unborn child.<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6fb47ee6-ba57-48f8-8c6d-90c264e4c044 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_612dfdd0-ed7d-47d1-9d3c-e46006e68845 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Breast-feeding</strong><strong> is not recommended in women living with</strong> <strong>HIV</strong> because HIV infection can be passed on to the baby in breast milk. <!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_5a67484b-fead-4fb9-bf28-74183384e5ff \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>A small amount of the ingredients in TRIUMEQ can also pass into your breast milk.</p><p>If you are breast-feeding, or thinking about breast-feeding:<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_cfd8a5a6-ac8f-4fa2-a544-d18d45c0afb9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> you should</strong> <strong>discuss it with </strong><strong>your doctor as soon as possible.</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1d8872b6-8df6-4ab2-8e89-ba5b4828fbd0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e7400f78-7ea8-4b89-9901-571f1bb02c2b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>TRIUMEQ can make you dizzy</strong> and have other side effects that make you less alert.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; <strong>Don&rsquo;t drive or operate machinery</strong> unless you are sure your alertness has not been affected.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a81d9700-e5aa-4f7f-99cb-6acdee2348c6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>TRIUMEQ</strong><strong> contains sodium.</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li><strong>The usual</strong><strong> dose is one tablet once a day</strong></li></ul><p>Swallow the tablet with some liquid. TRIUMEQ can be taken with or without food.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Children and adolescents aged between 12 and 17 years and weighing at least 40&nbsp;kg can take the adult dose of one tablet once a day.</p><p>&nbsp;</p><p><strong>Do not take an antacid</strong> during the 6 hours before you take TRIUMEQ, or for at least 2 hours after you take it.&nbsp; Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as TRIUMEQ.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&reg; Talk to your doctor for further advice on taking antacid medicines with TRIUMEQ.</p><p><strong>&nbsp;</strong></p><p><strong>If you take TRIUMEQ with food, you can take supplements or multivitamins containing calcium, iron or magnesium</strong> at the same time as TRIUMEQ. <strong>If you do not take TRIUMEQ with food, </strong>do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take TRIUMEQ, or for at least 2 hours after you take it.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg;Talk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with TRIUMEQ.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more TRIUMEQ than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_46e93ac9-d5c0-498f-b819-be4b1608e56c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too many tablets of TRIUMEQ, <strong>contact your doctor or pharmacist for advice</strong>. If possible, show them the TRIUMEQ pack.</p><p>&nbsp;</p><p><strong>If you forget to take TRIUMEQ</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1bb0d733-05d8-4947-a9bc-12bafc39c815 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you miss a dose, take it as soon as you remember.&nbsp; But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; <strong>Don&#39;t take a double dose </strong>to make up for a missed dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you have stopped taking TRIUMEQ</strong></p><p>If you have stopped taking TRIUMEQ for any reason &mdash; especially because you think you are having side effects, or because you have another illness:</p><p><strong>Talk to your doctor before you start taking it again</strong>. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may be related to a hypersensitivity reaction, <strong>you will be told never again to take TRIUMEQ, or any other medicine containing abacavir or dolutegravir</strong>. It is important that you follow this advice.</p><p>If your doctor advises that you can start taking TRIUMEQ again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>When you&rsquo;re being treated for HIV, it can be hard to tell whether a symptom is a side effect of TRIUMEQ or other medicines you are taking, or an effect of the HIV disease itself. <strong>So, it is very important to talk to your doctor about any changes in your health</strong>.</p><p>Abacavir can cause a hypersensitivity reaction (a serious allergic reaction), especially in people who carry a particular type of gene called HLA-B*5701. Even patients who don&rsquo;t have the HLA-B*5701 gene may still develop <strong>a hypersensitivity reaction</strong>, described in this leaflet in the panel headed &lsquo;Hypersensitivity reactions.&rsquo; <strong>It is very important that you read and understand the information about this serious reaction</strong>.</p><p>&nbsp;</p><p><strong>As well as the side effects listed below for TRIUMEQ</strong>, other conditions can develop during combination therapy for&nbsp;HIV.</p><p>&reg; It is important to read the information in this section under the heading &lsquo;Other possible side effects of combination therapy for&nbsp;HIV&rsquo;.</p><p>&nbsp;</p><p><strong>Hypersensitivity Reactions</strong></p><p>TRIUMEQ contains abacavir<strong> </strong>and dolutegravir<strong>. </strong>Both of these active substances can cause a serious allergic reaction known as a hypersensitivity reaction.</p><p>These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.</p><p><strong>&nbsp;</strong></p><p><strong>Who gets these reactions?</strong></p><p>Anyone taking TRIUMEQ could develop a hypersensitivity reaction, which could be life threatening if they continue to take TRIUMEQ.</p><p>You are more likely to develop this reaction if you have a gene called HLA-B*5701 (but you can get a reaction even if you don&rsquo;t have this gene). You should have been tested for this gene before TRIUMEQ was prescribed for you. If you know you have this gene, tell your doctor.</p><p>&nbsp;</p><p><strong>What are the symptoms?</strong></p><p>The most common symptoms are:</p><p><strong>fever </strong>(high temperature) and <strong>skin rash</strong>.</p><p>Other common symptoms are:</p><p><strong>nausea</strong> (feeling sick), <strong>vomiting</strong> (being sick), <strong>diarrhoea, abdominal </strong>(stomach) <strong>pain</strong>, <strong>severe tiredness</strong>.</p><p>Other symptoms include:</p><p>pains in the joints or muscles, swelling of the neck, shortness of breath, sore throat, cough, occasional headaches, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.</p><p><strong>&nbsp;</strong></p><p><strong>When do these reactions happen?</strong></p><p>Hypersensitivity reactions can start at any time during treatment with TRIUMEQ but are more likely during the first 6 weeks of treatment.</p><p><strong>Contact your doctor immediately:</strong></p><p><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get a skin rash, OR</strong></p><p><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get symptoms from at least 2 of the following groups:</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - fever </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - shortness of breath, sore throat or cough</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - nausea or vomiting, diarrhoea or abdominal pain</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - severe tiredness or aches and pains, or generally feeling ill.</strong></p><p><strong>Your doctor may advise you to stop taking TRIUMEQ.</strong></p><p>&nbsp;</p><p><strong>If you have stopped taking TRIUMEQ</strong></p><p>If you have stopped taking TRIUMEQ because of a hypersensitivity reaction, <strong>you must NEVER AGAIN take TRIUMEQ, or any other medicine containing abacavir.</strong> If you do, within hours, your blood pressure could fall dangerously low, which could result in death. You should also never again take medicines containing dolutegravir.</p><p>If you have stopped taking TRIUMEQ for any reason &mdash; especially because you think you are having side effects, or because you have other illness:</p><p><strong>Talk to your doctor before you start again.</strong> Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been, <strong>you will then be told never again to take TRIUMEQ, or any other medicine containing abacavir. </strong>You may also be told never again to take any other medicine containing dolutegravir. It is important that you follow this advice.</p><p>Occasionally, hypersensitivity reactions have developed in people who start taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.</p><p>Very rarely, patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have developed a hypersensitivity reaction when they start taking these medicines again.</p><p>If your doctor advises that you can start taking TRIUMEQ again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p><p>If you are hypersensitive to TRIUMEQ, return all your unused TRIUMEQ tablets for safe disposal. Ask your doctor or pharmacist for advice.</p><p>The TRIUMEQ pack includes an <strong>Alert Card</strong>, to remind you and medical staff about hypersensitivity reactions. <strong>Detach this card and keep it with you at all times</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty in sleeping (<em>insomnia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; lack of energy (<em>fatigue</em>)</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10</strong> <strong>people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; hypersensitivity reaction <em>(see &lsquo;Hypersensitivity reactions&rsquo; earlier in this section)</em></p><p>&middot;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp; itching (<em>pruritus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach (<em>abdominal</em>) pain</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach (<em>abdominal</em>) discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp; wind (<em>flatulence</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp; abnormal dreams</p><p>&middot;&nbsp;&nbsp;&nbsp; nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp; depression (feelings of deep sadness and unworthiness)</p><p>&middot;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp; fever <em>(high temperature)</em></p><p>&middot;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp; irritated or runny nose</p><p>&middot;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle pain and discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp; general feeling of being unwell</p><p>Common side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp;&nbsp; an increase in the level of liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; suicidal thoughts and behaviours (particularly in patients who have had depression or mental health problems before)</p><p>&middot;&nbsp;&nbsp;&nbsp; panic attack</p><p>Uncommon side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp;&nbsp; a decreased number of cells involved in blood clotting (<em>thrombocytopenia</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp; a low red blood cell count<em> (anaemia)</em> or low white blood cell count <em>(neutropenia)</em></p><p>&middot;&nbsp;&nbsp;&nbsp; an increase in sugar (glucose) in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp; an increase in triglycerides (type of fat) in the blood</p><p>&nbsp;</p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas <em>(pancreatitis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure (signs may include yellowing of the skin and the whites of the eyes or unusually dark urine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicide (particularly in patients who have had depression or mental health problems before)</p><p>&reg;<strong> &nbsp;Tell your doctor immediately</strong> if you experience any mental health problems (see also other mental health problems above).</p><p>Rare side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in bilirubin (a test of liver function)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in an enzyme called <em>amylase.</em></p><p>&nbsp;</p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingly feelings in the skin (pins and needles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of weakness in the limbs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) <em>(erythema multiforme)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals<em> (Stevens&ndash;Johnson syndrome)</em>, and a more severe form causing skin peeling in more than 30% of the body surface <em>(toxic epidermal necrolysis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (excess lactic acid in the blood).</p><p>Very rare side effects that may show up in blood tests are:<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a failure of the bone marrow to produce new red blood cells (<em>pure red cell aplasia</em>).</p><p>If you get any side effects</p><p><strong>&reg;</strong><strong> </strong><strong>Talk to your doctor</strong>. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Other possible side effects of combination therapy for HIV</strong></p><p>Combination therapy such as TRIUMEQ may cause other conditions to develop during HIV treatment.</p><p>&nbsp;</p><p><strong>Symptoms of infection and inflammation </strong></p><p>People with advanced HIV infection or AIDS have weak immune systems and are more likely to develop serious infections (<em>opportunistic infections</em>). Such infections may have been &ldquo;silent&rdquo; and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include <strong>fever</strong>, plus some of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&nbsp;</p><p>In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (<em>autoimmune disorders</em>).&nbsp; The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (rapid or irregular heartbeat) or tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity (excessive restlessness and movement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body.</p><p><strong>If you get any symptoms of infection</strong> and inflammation or if you notice any of the symptoms above:</p><p><strong>&reg;</strong><strong> </strong><strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>Joint pain, stiffness and bone problems</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. In this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they drink alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if their immune systems are very weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are overweight.</p><p><strong>Signs of osteonecrosis include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty moving.</p><p>If you notice any of these symptoms:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> </strong><strong>Tell your doctor</strong>.</p><p>&nbsp;</p><p><strong>Weight, blood lipid and blood glucose effects </strong></p><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d256d119-24a8-4c46-b1da-afbcd5491bfa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>Store TRIUMEQ below 30&deg;C.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0350db30-471b-4569-bc44-5a0aab574635 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Store in the original package in order to protect from moisture. Keep the bottle tightly closed. Do not remove the desiccant.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2c2bc0fb-8e65-4a05-833a-a24f12b022da \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p style="text-align:center"><strong>OUTER PACK IS INCLUDING THE FOLLOWING ALERT CARD</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:600px"><tbody><tr><td><p style="text-align:center"><strong>IMPORTANT&nbsp; -&nbsp; ALERT CARD</strong></p><p style="text-align:center"><strong>TRIUMEQ (dolutegravir/abacavir sulfate/lamivudine) Tablets</strong></p><p style="text-align:center"><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Since TRIUMEQ contains abacavir, some patients taking TRIUMEQ may develop a hypersensitivity reaction (serious allergic reaction) which can be life-threatening if treatment with TRIUMEQ is continued. <strong>CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking <em>TRIUMEQ</em> if:</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1)</strong></p></td><td style="vertical-align:top"><p><strong>you get a skin rash OR</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>2)</strong></p></td><td style="vertical-align:top"><p><strong>you get one or more symptoms from at least TWO of the following groups</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, sore throat or cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomiting or diarrhoea or abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe tiredness or achiness or generally ill feeling.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>If you have discontinued <em>TRIUMEQ</em> due to this reaction, <strong>YOU MUST NEVER TAKE </strong><em>TRIUMEQ</em>, or any other medicine containing abacavir (<em>ZIAGEN, KIVEXA</em> or <em>TRIZIVIR</em>) again as <strong>within hours</strong> you may experience a life-threatening lowering of your blood pressure or death.</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are dolutegravir, abacavir and lamivudine. Each tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir, 600 mg abacavir (as sulfate) and 300 mg lamivudine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><em><u>Tablet core:</u></em></p><p>D-Mannitol, microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, magnesium stearate, purified water.</p><p><em><u>Tablet coating: </u></em></p><p>Poly (vinyl) alcohol &ndash; partially hydrolyzed, titanium dioxide, macrogol/PEG, talc, iron oxide black and iron oxide red.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Triumeq film-coated tablets are purple, biconvex, film-coated oval tablets, debossed with “572 Trı” on one side.
The film-coated tablets are provided in bottles containing 30 tablets.
The bottle contains a desiccant to reduce moisture. Once the bottle has been opened keep the desiccant in the bottle, do not remove it. 
	
Not all pack sizes may be available in your country.

TRIUMEQ is a trademark owned by or licensed to the ViiV Healthcare group of companies.
©2024 ViiV Healthcare group of companies, all rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:<!--[if supportFields]><span lang=EN-US style='mso-bidi-font-size:
12.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
font-weight:normal'><span style='mso-element:field-begin'></span></span><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'> DOCVARIABLE
vault_nd_3d119787-ad01-4567-9560-4989570530f0 \* MERGEFORMAT </span><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;font-weight:normal'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;font-weight:normal'><span style='mso-element:
field-end'></span></span><![endif]--><!--[if supportFields]><span lang=EN-US
style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-font-kerning:0pt;font-weight:normal'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_026aec77-138b-41a7-8391-add80c4d221b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-font-kerning:0pt;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, UL. Grunwaldzka 189, 60-322 Poznan, Poland<!--[if supportFields]><span style='font-size:
12.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:#242424;background:white'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_52a95d96-2df3-4a8c-aed8-a8f8bb9b3efb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
color:#242424;background:white'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Marketing Authorization Holder:</strong><!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_20de6c95-d4a3-46ba-9f30-ef25e0aef93e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: UK Issue 28 Draft 1 
This leaflet was last revised in: 19 January 2024 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ترايوميك هو دواء يحتوي على ثلاث مواد فعالة تُستخدم لعلاج مرض نقص المناعة البشرية: أباكاڤير، لاميڤودين ودولوتيجراڤير. ينتمي أباكاڤير ولاميڤودين إلى فئة من مضادات الفيروسات الرجعية (الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية). تُسمى &rlm;‫<em>الأدوية النيوكليوزيدية المضادة لإنزيم المنتسخة العكسية</em><em> </em><em>)NRTI(</em>، وينتمي دولوتيجراڤير إلى فئة من مضادات الفيروسات الرجعية تُسمى &rlm;‫<em>مثبطات إنزيم الإنتيغراز </em><em>)INIs(</em>.</p><p dir="RTL">يستخدم ترايوميك في علاج <strong>عدوى الإيدز (فيروس نقص المناعة البشرية)</strong> لدى البالغين والمراهقين والأطفال فوق 12 عامًا، والذين لا يقل وزنهم عن 40 كيلو غرامًا.</p><p dir="RTL">قبل أن يصف لك الطبيب ترايوميك، فسوف يقوم بإجراء اختبار لك لمعرفة ما إذا كنت تحمل نوعًا معينًا من الجينات يسمى HLA-B*5701 أم لا. يجب عدم استخدام ترايوميك مع المرضى المعروفين بأنهم يحملون الجين HLA-B*5701. قد تزداد احتمالية تطور رد فعل فرط الحساسية (الأرجي) الشديد لدى المرضى الذين يحملون هذا الجين في حالة تناولهم ترايوميك (راجع &quot;تفاعلات فرط الحساسية&quot; في القسم 4).</p><p dir="RTL">إن ترايوميك لا يعالج تمامًا مرض نقص المناعة البشرية؛ وإنما يقلل من انتشار الفيروس في الجسم ويجعله في مستوى منخفض. كما يعمل على زيادة عدد خلايا CD4 (كتلة التمايز 4) المناعية في الدم. وخلايا CD4 (كتلة التمايز 4) هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">وتختلف استجابة المرضى للعلاج بعقار ترايوميك. سوف يراقب الطبيب مدى فعالية العلاج لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ترايوميك:</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_f60ce480-e013-47ca-b94e-f7cde6e8707e
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li dir="RTL">إذا كانت لديك <strong>حساسية</strong> <em>(فرط حساسية)</em> من دولوتيجراڤير، أو أباكاڤير (أو أي دواء آخر يحتوي على أباكاڤير)، أو لاميڤودين أو أي مكوّنات أخرى لهذا الدواء (المدرجة في القسم 6).</li><li dir="RTL"><strong>اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم </strong><strong>4</strong><strong>.</strong></li><li dir="RTL">إذا كنت تتناول دواءً يسمى&nbsp;<strong>فامبريدين</strong> (ويُعرَف أيضًا باسم دالفامبريدين، لعلاج حالات&nbsp;التصلب المتعدد(.</li></ul><p dir="RTL">&not; أخبر طبيبك إذا كنت تعتقد أن أيًا من هذه الحالات تنطبق عليك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL"><strong>مهم &mdash; تفاعلات فرط الحساسية</strong></p><p dir="RTL"><strong>يحتوي ترايوميك على أباكاڤير و دولوتيجراڤير.</strong> &rlm;‫ويمكن أن تتسبب هاتان المادتان الفعالتان في حدوث تفاعل أرجي خطير يعرف باسم تفاعل فرط الحساسية. يجب ألا تتناول أبدًا دواء أباكاڤير أو المنتجات التي تحتوي على أباكاڤير مرة أخرى إذا ظهرت عليك أية تفاعلات فرط الحساسية، فقد يُشكّل ذلك خطرًا على حياتك.</p><p dir="RTL"><strong>يجب عليك قراءة جميع المعلومات الواردة ضمن &quot;تفاعلات فرط الحساسية&quot; بعناية في الجزء الخاص بها من القسم </strong><strong>4</strong><strong>.</strong></p><p dir="RTL">تحتوي عبوة ترايوميك على <strong>بطاقة تنبيه</strong> لتذكيرك ,وتذكير الطاقم الطبي بتفاعل فرط الحساسية. <strong>افصل هذه البطاقة واحتفظ بها معك طوال الوقت</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجي توخي الحذر عند تناول دواء تريوميك</strong></p><p dir="RTL">بعض المرضى الذين يتناولون ترايوميك أو غيره من العلاجات المركبة لفيروس نقص المناعة البشرية يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة مقارنةً بغيرهم. يجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض متوسط أو حاد في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت سابقًا <strong>بمرض في الكبد</strong>، بما في ذلك إلتهاب الكبد الوبائي (بي) أو (سي) (إذا كنت مصابًا بعدوى إلتهاب الكبد الوبائي (بي)، فلا تتوقف عن تناول ترايوميك بدون استشارة الطبيب، إذ قد يعاودك إلتهاب الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشكلة في الكلى</p><p dir="RTL">&not; <strong>استشر طبيبك إذا كنت تعاني من أي من الأمراض سالفة الذكر قبل تناول ترايوميك.</strong> قد تحتاج إلى إجراء المزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول الدواء. راجع القسم 4 لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاعلات فرط الحساسية من أباكاڤير</u></p><p dir="RTL">حتى المرضى الذين لا يوجد لديهم جين HLA-B*5701 قد يصابون <strong>بتفاعل فرط الحساسية</strong> (تفاعل أرجي خطير).</p><p dir="RTL"><strong>&not;</strong><strong> اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم </strong><strong>4</strong><strong> من هذه النشرة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>خطر الإصابة </u><u>&nbsp;</u><u>بأمراض القلب والأوعية الدموية.</u></p><p dir="RTL">لا يمكن استبعاد أن أباكاڤير قد يزيد من خطر الإصابة بأمراض القلب والأوعية الدموية.</p><p dir="RTL">&not; <strong>أخبر طبيبك</strong> إذا كنت تعاني من مشاكل في القلب والأوعية الدموية أو كنت تدخن أو تعاني من أي أمراض أخرى قد تزيد من خطر الإصابة بأمراض القلب والأوعية الدموية ، مثل ارتفاع ضغط الدم أو مرض السكري. لا تتوقف عن تناول ترايوميك ما لم ينصحك الطبيب بهذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>انتبه للأعراض الخطيرة</u><!--[if supportFields]><u><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></u><u><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></u><span dir=RTL></span><span
dir=RTL></span><u><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></u><u><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_e736ce95-5107-4ce0-b7ec-173eb41ded03
\* MERGEFORMAT</span></u><span dir=RTL></span><span dir=RTL></span><u><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p dir="RTL">قد تتطور لدى بعض الأشخاص الذين يتناولون أدوية لعلاج عدوى الإيدز (فيروس نقص المناعة البشرية) بعض الحالات الأخرى التي قد تكون خطيرة. ويشمل ذلك ما يلي:<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_4696125d-eb9b-4e8f-b347-5510151bb586 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><ul><li dir="RTL">أعراض العدوى والإلتهاب</li><li dir="RTL">آلام وتيبس المفاصل ومشكلات العظام</li></ul><p dir="RTL">يجب عليك معرفة العلامات والأعراض المهمة التي يجب الحذر منها أثناء تناول ترايوميك.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_c94d1d2b-b684-4a90-ad3f-8064c25216e4
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&not;</strong><strong> اقرأ المعلومات الموجودة في &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية&quot; في القسم </strong><strong>4</strong><strong> من هذه النشرة.</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_cca69779-a350-440f-b769-7c91db3163df
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لا تعطي هذا الدواء للأطفال الأقل من 12 عامًا. لم تتم دراسة استخدام ترايوميك في حالات الأطفال الأقل من 12 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار ترايوميك</strong></p><p dir="RTL">قم بإبلاغ طبيبك إذا كنت تتناول أي أدوية أخرى، أو تناولت أي أدوية مؤخرًا، أو يحتمل أن تتناول أي أدوية.</p><p dir="RTL">لا تتناول ترايوميك مع هذه الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء&nbsp;فامبريدين (ويُعرَف أيضًا باسم دالفامبريدين) المستخدم في علاج حالات&nbsp;<strong>التصلب المتعدد</strong><strong>.</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على فاعلية علاج ترايوميك للمرض أو يمكن أن تزيد من احتمال التعرّض للآثار الجانبية.&nbsp;<br />يمكن أن يؤثر ترايوميك على فعالية بعض الأدوية الأخرى.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب</strong> في حالة تناول أيًا من الأدوية المذكورة <em>في القائمة التالية</em>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين لعلاج <strong>السكري</strong></p><ul><li dir="RTL">الأدوية المعروفة باسم <strong>مضادات الحموضة</strong> لعلاج <strong>عسر الهضم</strong> و<strong>الحموضة المعوية</strong>. <strong>لا تتناول دواءً مضادًا للحموضة</strong> خلال 6 ساعات قبل تناول ترايوميك، أو خلال ساعتين على الأقل بعد تناوله. <em>(انظر أيضًا القسم </em><em>3</em><em>)</em>.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكملات الغذائية أو الأقراص متعددة الفيتامينات التي تحتوي على الكالسيوم أو الحديد أو المغنيسيوم. <strong>إذا كنت تتناول تريوميك مع الطعام،</strong> فيمكنك تناول المكملات الغذائية أو الفيتامينات المتعددة التي تحتوي على الكالسيوم أو الحديد أو الماغنيسيوم في نفس الوقت مع تريوميك. <strong>إذا كنت لا تتناول تريوميك مع الطعام، </strong><strong>لا تتناول المكملات الغذائية أو الأقراص متعددة الفيتامينات التي تحتوي على الكالسيوم أو الحديد أو المغنيسيوم</strong> خلال 6 ساعات قبل تناول ترايوميك وخلال ساعتين على الأقل بعد تناوله <em>(انظر أيضًا القسم </em><em>3</em><em>)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمتريسيتابين أو إتراڤيرين أو إيفاڤيرينز أو نيڤيرابين أو تبراناڤير/ريتوناڤير لعلاج <strong>عدوى نقص المناعة البشرية</strong></p><ul><li dir="RTL">الأدوية (السائلة عادةً) التي تحتوي على السوربيتول أو غيره من الكحولات السكرية (مثل زيليتول أو مانيتول أو لاكتيتول أو مالتيتول)، إذا كان تناولها يتم بشكل منتظم</li><li dir="RTL">الأدوية الأخرى التي تحتوي على لاميڤودين، المستخدم في علاج <strong>عدوى الإيدز (فيروس نقص المناعة البشرية)</strong> أو <strong>عدوى إلتهاب الكبد الوبائي (بي)</strong></li><li dir="RTL">كلادريبين، المستخدم في علاج <strong>ابيضاض خلايا الدم (سرطان الدم) المشعره</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين لعلاج السل وغيره من <strong>أمراض العدوى البكتيرية</strong></p><ul><li dir="RTL">ترايميثوبريم/سلفاميثوكسازول، مضاد حيوي لعلاج <strong>العدوى البكتيرية</strong></li><li dir="RTL">فينيتوين وفينوباربيتال لعلاج <strong>الصرع</strong></li><li dir="RTL">أوكسكاربازيبين وكاربامازيبين لعلاج <strong>الصرع</strong>&nbsp; و<strong>الاضطراب ثنائي القطب</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نبتة سانت جونز</strong> <em>(العرن المثقوب)</em>، وهو علاج عشبي لعلاج <strong>الاكتئاب</strong></p><ul><li dir="RTL"><strong>الميثادون</strong>، المستخدم <strong>كبديل للهيروين</strong>. يزيد أباكاڤير من معدل تخلص الجسم من ميثادون. إذا كنت تتناول ميثادون، فسيتم فحصك لعلاج أي أعراض انسحاب. قد ينبغي تعديل جرعة ميثادون الخاصة بك.</li><li dir="RTL">دواء <strong>ريوسيجوات</strong>، الذى يُستخدم <strong>لعلاج ارتفاع ضغط الدم في الأوعية الدموية</strong> (الشرايين الرئوية)، التي تنقل الدم من القلب إلى الرئتين، قد يحتاج الطبيب المعالج إلى تقليل جرعة ريوسيجوات الخاصة بك، لأن المادة الفعالة أباكاڤير تزيد من مستويات دواء ريوسيجوات في الدم.</li></ul><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>ينبغي إخبار الطبيب أو الصيدلي</strong> إذا كنت تتناول أيًا من هذه الأدوية. قد يقرر طبيبك تعديل الجرعة أو حاجتك إلى إجراء المزيد من الفحوصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_62616156-dc1f-4c16-ad84-301595553242
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا &rlm;‫كنتِ حاملاً أو تظنين أنكِ حامل أو إذا كنتِ تخططين للإنجاب:<!--[if supportFields]><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_22724062-6363-4904-ae14-ac8c2582ef34 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>تحدثي مع طبيبكِ</strong> حول مخاطر وفوائد تناول ترايوميك.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_93276acb-269a-4c15-9382-931c8ee060ad
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">إن تناول ترايوميك أثناء الحمل أو خلال الأسابيع الستة الأولى من الحمل قد يزيد من خطر حدوث عيب خلقي للجنين، يسمى عيب الأنبوب العصبي، مثل السنسنة المشقوقة (تشوه الحبل الشوكي).<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_07d4241d-6ed3-495d-8075-187bf4aeb5aa
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">في حالة احتمالية حدوث حمل أثناء تلقي العلاج بترايوميك،<!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>VAULT_ND_dc7578b1-ba0a-43b2-ae76-ac23da8a7d1e
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;<strong>&ccedil;</strong> <strong>تحدثي إلى طبيبكِ </strong>لمناقشة مدى الحاجة إلى استخدام وسائل منع الحمل مثل الواقي الذكري أو حبوب منع الحمل.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_8a2b9a8e-b9af-4b73-9f5d-a71207699175
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">أخبري الطبيب على الفور في حالة حدوث حمل أو كنتِ تنوين الإنجاب. وسيراجع معكِ الطبيب علاجكِ. لا تتوقفي عن تناول ترايوميك دون استشارة طبيبكِ، لأن هذا قد يضر بكِ وبالجنين.<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_6aadd026-18ad-407d-9e5f-b438a31a7b92 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> </span></b><b><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'>VAULT_ND_448dc57f-2733-43ce-9c91-4d4c891d97e1 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>لا ينصح </strong><strong>بالرضاعة من قبل النساء المتعايشات مع مرض نقص المناعة البشرية</strong> لأن عدوى فيروس نقص المناعة البشرية يمكنها الانتقال إلى الطفل عبر حليب الأم. <!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span></span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>VAULT_ND_235b00ac-97dc-456f-ae90-61b7c4d1029e
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">ويمكن أن تنتقل كمية بسيطة من مكونات ترايوميك إلى الطفل عبر حليب الأم.</p><p dir="RTL">إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين في ذلك:<!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-bidi-font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'>VAULT_ND_7efc346a-f8ed-4d1b-ab41-d5ec00628aa4
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&not;</strong><strong> </strong><strong>&nbsp;</strong><strong>يجب عليكِ مناقشة هذا الأمر مع طبيبكِ في أقرب وقت ممكن </strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_c5a93eeb-b14f-47d9-be2f-f720ded4054d
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>يمكن أن يصيبك ترايوميك بالدوار</strong> وغيره من الأعراض الجانبية التي تجعلك أقل انتباهًا.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>تجنب القيادة أو تشغيل الآلات</strong> ما لم تتأكد من عدم تأثر انتباهك.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_5d830c6b-e463-44a8-b179-10c3225c2514
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء تريوميك على الصوديوم.</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملجم) لكل قرص مغلف، وهو ما يعني بشكل أساسي أنه &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الالتزام بدقة بتعليمات الطبيب بشأن طريقة تناول هذا الدواء. راجع طبيبك أو الصيدلي في حالة عدم التأكد بشأن طريقة الاستعمال.</p><ul><li dir="RTL"><strong>الجرعة العادية هي قرص واحد مرة واحدة في اليوم</strong></li></ul><p dir="RTL">ابتلع القرص مع كمية من السوائل. يمكن تناول ترايوميك مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p dir="RTL">يمكن للأطفال والمراهقين الذين تتراوح أعمارهم بين 12 و17 عامًا ولا يقل وزنهم عن 40 كلجم أخذ جرعة البالغين، وهي قرص واحد مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول دواءً مضادًا للحموضة</strong> خلال 6 ساعات قبل تناول ترايوميك، أو خلال ساعتين على الأقل بعد تناوله.&nbsp;<br />يمكن تناول الأدوية الأخرى التي تقلل الحموضة، مثل الرانيتيدين والأوميبرازول في نفس الوقت مع ترايوميك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&not; استشر الطبيب للحصول على إرشادات تناول الأدوية التي تقلل الحموضة مع ترايوميك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول تريوميك مع الطعام،</strong> <strong>فيمكنك تناول المكملات الغذائية أو الفيتامينات المتعددة التي تحتوي على الكالسيوم أو الحديد أو الماغنيسيوم </strong>في نفس الوقت مع تريوميك. <strong>إذا كنت لا تتناول تريوميك مع الطعام، </strong>لا تتناول المكملات الغذائية أو الأقراص متعددة الفيتامينات التي تحتوي على الكالسيوم أو الحديد أو المغنيسيوم<strong> </strong>خلال 6 ساعات قبل تناول ترايوميك، أو خلال ساعتين على الأقل<br />بعد تناوله.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; استشر الطبيب للحصول على إرشادات تناول المكملات الغذائية أو الأقراص متعددة الفيتامينات التي تحتوي على الكالسيوم أو الحديد أو المغنيسيوم مع ترايوميك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة ترايوميك زائدة عن ما ينبغي تناوله</strong><!--[if supportFields]><b><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_36f90d6b-491f-440c-8245-fe026ca7b034
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">عند تناول عدد كبير من أقراص ترايوميك، <strong>استشر الطبيب أو الصيدلي</strong>. ويُفضل أن تريهم عبوة ترايوميك إن أمكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيان تناول ترايوميك</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'>VAULT_ND_d0878df9-8f5f-4db5-8fc1-a0b811268e7f
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا فاتتك جرعة، تناولها فور تذكرها. لكن إذا كان موعد الجرعة التالية يحل خلال 4 ساعات، فاقتصر على تناول الجرعة التالية في موعدها المحدد. ثم أكمل العلاج كما في السابق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>لا تتناول جرعة مضاعفة</strong> لتعويض الجرعة التي فاتتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال التوقف عن تناول ترايوميك</strong></p><p dir="RTL">في حال التوقف عن تناول ترايوميك لأي سبب من الأسباب - خاصة إذا كنت تعتقد إصابتك ببعض الأعراض الجانبية أو أي مرض آخر:</p><p dir="RTL"><strong>تحدث إلى طبيبك قبل استئناف تناول الدواء</strong>. سوف يتحقق الطبيب من علاقة هذه الأعراض بتفاعل فرط الحساسية. إذا رأى الطبيب أن هذه الأعراض قد تكون مرتبطة بتفاعل فرط الحساسية، <strong>فسوف يُطلب منك عدم تناول ترايوميك مرة أخرى أو أي دواء آخر يحتوي على أباكاڤير أو دولوتيجراڤير</strong>. من المهم الالتزام بهذه النصيحة.</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول ترايوميك مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على العناية الطبية إذا لزم الأمر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء، مثل جميع الأدوية، في حدوث آثار جانبية، و بالرغم من ﺫلك &nbsp;ليس بالضرورة أن يصاب بها جميع الأشخاص.</p><p dir="RTL">أثناء العلاج من فيروس نقص المناعة البشرية، قد يصعب تحديد ما إذا كان أي عرض يطرأ هو أثر جانبي لتناول دواء ترايوميك أو أي أدوية أخرى تتناولها، أم أثر طبيعي لفيروس نقص المناعة البشرية ذاته. <strong>لذا، من المهم جدًا استشارة الطبيب عندما تطرأ أي تغيرات على صحتك</strong>.</p><p dir="RTL">يمكن أن يسبب أباكاڤير أعراض الحساسية المفرطة (رد فعل تحسسي خطير)، خاصة عند الأشخاص الذين لديهم نوعًا معينًا من الجينات يسمى HLA-B * 5701. حتى المرضى الذين لا يوجد لديهم جين HLA-B*5701 قد يصابون <strong>بتفاعل فرط الحساسية</strong>، كما هو موضح في جزء &quot;تفاعلات فرط الحساسية&quot; بهذه النشرة. <strong>من المهم جدًا قراءة المعلومات المتعلقة بهذا التفاعل الخطير وفهمها جيدًا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاوة على الآثار الجانبية الموضحة أدناه لدواء ترايوميك</strong>، يمكن أن تتطور بعض الحالات الأخرى أثناء العلاج المركب لفيروس نقص المناعة البشرية.</p><p dir="RTL">&not;&nbsp; من المهم قراءة المعلومات الموجودة في جزء &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات فرط الحساسية </strong></p><p dir="RTL">يحتوي ترايوميك على أباكاڤير ودولوتيجراڤير. ويمكن أن تتسبب هاتان المادتان الفعالتان في حدوث تفاعل أرجي خطير يعرف باسم تفاعل فرط الحساسية.</p><p dir="RTL">يشيع حدوث تفاعلات فرط الحساسية لدى المرضى الذين يتناولون أدوية تحتوي على أباكاڤير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من الذي يتعرض لهذه التفاعلات؟</strong></p><p dir="RTL">يمكن أن يعاني أي شخص يتناول ترايوميك من تفاعل فرط الحساسية، وهو الأمر الذي يمكنه تهديد حياته إذا استمر في تناوله.</p><p dir="RTL">ويزيد احتمال التعرض لهذا التفاعل في حالة وجود جين باسم HLA-B*5701 (ويظل احتمال الإصابة قائمًا حتى في حالة عدم وجود هذا الجين). ينبغي فحصك لتحديد وجود هذا الجين قبل وصف دواء ترايوميك لك. إذا كنت على علم بوجود هذا الجين، فأخبر الطبيب قبل تناول ترايوميك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الأعراض؟</strong></p><p dir="RTL">أكثر الأعراض شيوعًا هي:</p><p dir="RTL"><strong>الحمى</strong> (ارتفاع درجات الحرارة) و<strong>الطفح الجلدي</strong>.</p><p dir="RTL">الأعراض الشائعة الأخرى هي:</p><p dir="RTL"><strong>الغثيان</strong> (الدوار)، <strong>القيء </strong>(الاستفراغ)، <strong>الإسهال</strong>، <strong>آلام البطن</strong> (المعدة)، <strong>الإرهاق الشديد</strong>.</p><p dir="RTL">تشمل الأعراض الأخرى:</p><p dir="RTL">آلام في المفاصل أو العضلات، أو تورم في العنق، أو ضيق التنفس، أو إلتهاب الحلق، أو السعال، أو تكرار الشعور بالصداع، أو إلتهاب في العين (إلتهاب الملتحمة)، أو قرحات في الفم، أو انخفاض في ضغط الدم، أو وخز أو تنميل في اليدين أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تحدث هذه التفاعلات؟</strong></p><p dir="RTL">يمكن أن تظهر تفاعلات فرط الحساسية في أي وقت خلال فترة العلاج باستخدام ترايوميك ولكن الغالب وقوعها في الأسابيع الستة الأولى.</p><p dir="RTL"><strong>اتصل بالطبيب فورًا:</strong></p><p dir="RTL"><strong>1</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ظهور طفح جلدي أو</strong></p><p dir="RTL"><strong>2</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت لديك أعراض مجموعتين على الأقل من المجموعات التالية:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الحمى </strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - ضيق النفس أو إلتهاب الحلق أو السعال</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الغثيان أو القيء، أو الإسهال أو آلام البطن</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الإجهاد أو الأوجاع والإرهاق الشديد، أو الشعور بالإعياء بشكل عام.</strong></p><p dir="RTL"><strong>قد ينصحك الطبيب بالتوقف عن تناول ترايوميك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حال التوقف عن تناول ترايوميك</strong></p><p dir="RTL">إذا توقفت عن تناول ترايوميك بسبب تفاعل فرط الحساسية، <strong>فيجب عليك عدم تناول ترايوميك مرة أخرى على الإطلاق، أو أي دواء يحتوي على أباكاڤير</strong>. فإن حدث وتناولت الدواء، فمن الممكن أن يحدث انخفاض حاد في ضغط الدم يؤدي إلى الوفاة. كذلك احذر أن تتناول أي أدوية تحتوي على دولوتيجراڤير.</p><p dir="RTL">في حال التوقف عن تناول ترايوميك لأي سبب من الأسباب، خاصة إذا كنت تعتقد أنك تعاني من بعض الأعراض الجانبية أو أنك مُصاب بأي مرض آخر:</p><p dir="RTL"><strong>فلا بد من استشارة الطبيب قبل استئناف تناول الدواء</strong>. سوف يتحقق الطبيب من علاقة هذه الأعراض بتفاعل فرط الحساسية. إذا رأى الطبيب أن هذه الأعراض قد تكون مرتبطة بالحساسية، <strong>فسوف يطلب منك عدم تناول ترايوميك مجددًا وكذلك أي دواء يحتوي على</strong><strong> </strong><strong>أباكاڤير.</strong> وربما يُطلب منك كذلك عدم تناول أي أدوية تحتوي على دولوتيجراڤير. من المهم الالتزام بهذه النصيحة.</p><p dir="RTL">أحيانًا تظهر تفاعلات فرط الحساسية لدى المرضى الذين بدأوا في تناول مستحضرات تحتوي على أباكاڤير مجددًا، والذين قد سبق أن احتوت بطاقة التنبيه الخاصة بهم على عرَض واحد فقط من هذه الأعراض قبل التوقف عن تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من النادر جدًا أن يظهر تفاعل فرط الحساسية لدى المرضى الذين سبق أن تناولوا أدوية تحتوي على أباكاڤير ولم تظهر عليهم أي أعراض فرط الحساسية، عندما يبدأون في تناول هذه الأدوية مرة أخرى.</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول ترايوميك مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على العناية الطبية إذا لزم الأمر.</p><p dir="RTL">إذا كنت تعاني من فرط الحساسية لعقار ترايوميك، فأعد جميع الأقراص غير المستخدمة حتى يتم التخلص منها بشكل آمن. يجب استشارة الطبيب أو الصيدلي.</p><p dir="RTL">تحتوي عبوة ترايوميك على <strong>بطاقة تنبيه</strong> لتذكيرك بالأمور الطبية المتعلقة بتفاعلات فرط الحساسية. <strong>افصل هذه البطاقة واحتفظ بها معك طوال الوقت</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا </strong></p><p dir="RTL">قد تصيب <strong>أكثر &rlm;</strong>‫<strong>من شخص واحد من كل </strong><strong>10</strong><strong> أشخاص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور بالتوعك <em>(الغثيان)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صعوبة في النوم <em>(الأرق)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الطاقة <em>(التعب)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>10</strong><strong> أشخاص</strong>​​:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تفاعل فرط الحساسية <em>(راجع &quot;تفاعلات فرط الحساسية&quot; في جزء سابق من هذا القسم)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>حكة <em>(جلدية)</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>إعياء <em>(قيء)</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>ألم في المعدة <em>(ألم في البطن)</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>مغص <em>(ألم في المعدة)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ريح <em>(انتفاخ بسبب الغازات)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أحلام مزعجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; كوابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اكتئاب (شعور بالحزن الشديد وعدم الجدارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إجهاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>الحمى <em>(ارتفاع درجة الحرارة)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تهيج أو رشح الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم وعدم راحة في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور العام بعدم الراحة</p><p dir="RTL">من بين الآثار الجانبية الشائعة التي تظهرها فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة في مستوى إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>100</strong><strong> شخص</strong>:</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>إلتهاب الكبد <em>(إلتهاب الكبد الوبائي) </em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أفكار وسلوكيات انتحارية (تحديدًا لدى المرضى الذين سبق أن عانوا من الاكتئاب أو من مشاكل نفسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; نوبات الهلع</p><p dir="RTL">من بين الآثار الجانبية غير الشائعة التي تظهرها فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض في عدد الخلايا المشاركة في تجلط الدم <em>(قلة الصفيحات)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء <em>(الأنيميا)</em> أو انخفاض في عدد خلايا الدم البيضاء <em>(قلة العدلات)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة السكر (الجلوكوز) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة ثلاثي الغليسريد (نوع من الدهون) في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>1000</strong><strong> شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب في البنكرياس <em>(إلتهاب البنكرياس)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق في الأنسجة العضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي (قد تشمل العلامات اصفرار الجلد وبياض العينين أو البول الداكن بشكل غير عادي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتحار (لاسيما لدى المرضى الذين عانوا من قبل من نوبات الاكتئاب أو مشاكل في الصحة العقلية)</p><p dir="RTL">&nbsp;&not;<strong>أخبر الطبيب على الفور</strong> إذا كنت تعاني من أي مشاكل في الصحة العقلية (انظر أيضًا مشاكل الصحة العقلية الأخرى سالفة الذكر).</p><p dir="RTL">الآثار الجانبية النادرة التي قد تظهر في فحوصات الدم هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى البيليروبين (تحليل لوظائف الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيم يُعرف باسم الأميلاز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>10000</strong><strong> شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل، الشعور بالوخز في الجلد (كأنه وخز بالإبر والدبابيس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بضعف في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يسبب تقرحات ويبدو مثل الأهداف الصغيرة (بقع سوداء في المنتصف محاطة بمنطقة شاحبة مع حلقة سوداء حول الحافة) <em>(حُمامَى عديدة الأشكال)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي منتشر مع تقرحات وتقشّر الجلد خاصة حول الفم والأنف والعينين والأعضاء التناسلية <em>(متلازمة ستيفنز جونسون)</em>، وشكل أكثر حدة يؤدي إلى تقشر الجلد في أكثر من 30٪ من سطح الجسم <em>(تقشر الأنسجة المتموتة البشروية التسممي)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُماض لاكتيكي (مستويات زائدة من حمض اللاكتيك في الدم).</p><p dir="RTL">من بين الآثار الجانبية شديدة الندرة التي تظهرها فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النخاع العظمي في إنتاج خلايا دم حمراء جديدة <em>(عدم تنسج كريات دم حمراء نقية)</em>.</p><p dir="RTL">في حالة الإصابة بالآثار الجانبية</p><p dir="RTL">&not; <strong>تحدث إلى طبيبك</strong>. وهذا يتضمن أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية</strong></p><p dir="RTL">يمكن أن يؤدي العلاج المركب مثل دواء ترايوميك إلى تطور حالات أخرى أثناء علاج فيروس نقص المناعة البشرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض العدوى والإلتهاب </strong></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى الإيدز أو فيروس نقص المناعة البشرية من أجهزة مناعية ضعيفة، ويصبحون أكثر عرضة للإصابة بعدوى خطيرة<em> (عدوى انتهازية)</em>. قد لا تعلن هذه العدوى عن نفسها ولا تُظهر أي أعراض، وبالتالي لن يكتشفها الجهاز المناعي الضعيف قبل بدء العلاج. بعد بدء العلاج، يصبح الجهاز المناعي أكثر قوة، ويهاجم العدوى، مما يؤدي إلى ظهور أعراض العدوى أو الإلتهاب. عادة ما تشمل الأعراض ​<strong>الحمى</strong>​، بالإضافة إلى بعض من الأعراض التالية:​</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">​</p><p dir="RTL">في حالات نادرة، بمجرد أن يصبح الجهاز المناعي أكثر قوة، قد يهاجم أنسجة الجسم السليمة <em>(​اضطرابات المناعة الذاتية)</em>. وربما تظهر أعراض اضطرابات المناعة الذاتية بعد أشهر من تناول الدواء لعلاج عدوى فيروس نقص المناعة البشرية. قد تشمل الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب (ضربات قلب سريعة أو غير منتظمة) أو الارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط (التململ والحركة الزائدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين وينتقل لأعلى البدن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني من أي من أعراض العدوى</strong> والإلتهاب، أو لاحظت أيًا من الأعراض المذكورة أعلاه:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>يجب إبلاغ الطبيب على الفور</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى بدون استشارة الطبيب.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>آلام وتيبس المفاصل ومشكلات العظام</strong></p><p dir="RTL">​يظهر لدى بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشرية حالة يُطلق عليها ​<em>النخر العظمي</em>​. في هذه الحالة، تموت أجزاء من أنسجة العظام بسبب انخفاض تدفق الدم إلى العظام. تزداد احتمالية الإصابة بهذه الحالة لدى الأشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون علاجًا مركبًا لفترة طويلة من الوقت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون الأدوية المضادة للإلتهابات التي يُطلق عليها الكورتيكوستيرويدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يتناولون مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من ضعف شديد في جهازهم المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا يعانون من زيادة الوزن.</p><p dir="RTL"><strong>تشمل علامات النخر العظمي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام (وخاصة في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الحركة.</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&not;</strong><strong> أخبر طبيبك.</strong><strong> </strong></p><p>&nbsp;</p><p><strong>زيادة الوزن ودهون الدم وجلوكوز الدم</strong></p><p dir="RTL">أثناء علاج فيروس نقص المناعة البشرية، ربما تحدث زيادة في الوزن وزيادة في مستويات الدهون في الدم وجلوكوز الدم. ويرتبط ذلك جزئيًا باستعادة الصحة وأسلوب المعيشة وأحيانًا بأدوية فيروس نقص المناعة البشرية نفسها. وسيختبر الطبيب مدى تأثير هذه التغييرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ا<strong>لإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">في حالة ظهور أي أعراض جانبية، قم بإبلاغ الطبيب أو الصيدلي. وهذا يتضمن أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى العبوة بعد كلمة &quot;EXP&quot;. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يحفظ ترايوميك في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يجب تخزينه في عبوته الأصلية لحفظه من الرطوبة. يجب قفل القارورة بإحكام. يجب عدم إزالة مانع الرطوبة.</p><p dir="RTL">لا تتخلص من الأدوية في الفضلات السائلة ولا المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات من شأنها أن تحافظ على البيئة.</p><p dir="RTL">&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL" style="text-align:center"><strong>تحتوي العبوة الخارجية على بطاقة التنبيه التالية</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:600px"><tbody><tr><td><p style="text-align:center"><strong>هام&nbsp; -&nbsp; بطاقة التنبيه</strong></p><p style="text-align:center"><strong>أقراص ترايوميك (دولوتيجراڤير/أباكاڤير/لاميڤودين)</strong></p><p style="text-align:center"><strong>احتفظ بهذه البطاقة معك طوال الوقت</strong></p></td></tr></tbody></table><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">نظرًا لاحتواء ترايوميك على أباكاڤير، فإن بعض المرضى الذين يتناولون ترايوميك قد يعانون من تفاعل<br />فرط الحساسية (تفاعل أرجي خطير) يمكنه أن يهدد حياة الشخص إذا استمر العلاج باستخدام ترايوميك.<br /><strong>اتصل بالطبيب فورًا لاستشارته في التوقف عن تناول <em>ترايوميك</em></strong><strong><em> </em></strong><strong>إذا:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ظهر لديك طفح جلدي أو</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>إذا ظهر لديك واحد أو أكثر من أعراض مجموعتين على الأقل من المجموعات التالية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس أو إلتهاب الحلق أو السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء أو الإسهال أو ألم في المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد أو الألم الشديد أو الشعور بالتعب عامة.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">إذا توقفت عن تناول <em>ترايوميك</em><em> </em>بسبب هذا التفاعل، <strong>يتعين عليك ألا تتناول</strong> <em>ترايوميك</em>، أو أي دواء يحتوي على أباكاڤير (<em>زياجن</em> أو <em>كيفيكسا</em> أو <em>تريزيفير</em>) مرة أخرى لأنك في <strong>خلال ساعات</strong> قد تتعرض لانخفاض حاد في ضغط الدم يهدد حياتك وربما تتعرض للموت.</p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي دولوتيجراڤير وأباكاڤير ولاميڤودين. كل قرص يحتوي على صوديوم دولوتيجراڤير يعادل 50 ملجم من الدولوتيجراڤير، 600 ملجم أباكاڤير (على هيئة سلفات) بالإضافة الى 300 ملجم لاميڤودين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><em><u>لب القرص:</u></em></p><p dir="RTL">دي - مانيتول، سليلوز دقيق التبلور، بوفيدون (K29/32)، غليكولات النشاء الصودي، سترات الماغنيسيوم، ماء منقّى.</p><p dir="RTL"><em><u>غلاف القرص: &nbsp;</u></em></p><p dir="RTL">كحول عديد )الفينيل( - متحلل جزئيا، ثاني أكسيد التيتانيوم، ماكروغول/PEG، تلك، أكسيد حديد أسود وأكسيد حديد أحمر.</p><p dir="RTL">- يحتوي هذا الدواء على أقل من 1 ملي مول صوديوم (23 ملجم) لكل قرص، وهذا يعني بشكل أساسي &quot;خالي من الصوديوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ترايوميك ذات لون أرجواني، ومحدبة من الجانبين، وبيضاوية الشكل، منقوش عليها &quot;572 Trı&quot; على جانب واحد.</p><p dir="RTL">تتوفر الأقراص في زجاجة تحتوي على 30 قرصًا.</p><p dir="RTL">تحتوي الزجاجة على مادة مجففة لتقليل الرطوبة. عند فتح الزجاجة، احتفظ بالمجفف فيها ولا تتخلص منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p><p dir="RTL">ترايوميك هي علامة تجارية مملوكة أو مرخصة لمجموعة شركات ڤيڤ هيلثكير.</p><p dir="RTL">&copy; 2024 مجموعة شركات ڤيڤ هيلثكير. جميع الحقوق محفوظة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المُصنعة:</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-US dir=LTR style='font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'>VAULT_ND_e5556913-ccd2-45cb-a641-e35263a72e43 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-US
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p><strong>مالك التسويق المعتمد</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-US dir=LTR style='font-size:11.0pt;
mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'>VAULT_ND_cbe948bb-d6e7-43fc-afa4-c6750484a1e7 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-US
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-bidi-font-weight:bold'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p>العنوان: صندوق بريد ٢٢٦١٧ ، جدة ٢١٤١٦ ، المملكة العربية السعودية</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم النسخة: UK Issue 28 Draft 1 
تمت آخر مراجعة لهذه النشرة في:  19 يناير 2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Triumeq 50 mg/600 mg/300 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 50 mg dolutegravir (as sodium), 600 mg of abacavir (as sulfate) and 300 mg of lamivudine.

For the full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

Purple, biconvex, film-coated oval tablets, approximately 22 x 11 mm, debossed with “572 Trı” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see sections 4.4 and 5.1).</p><p>Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be prescribed by a physician experienced in the management of HIV infection.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:#00B050'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0fb0b4f3-7752-4990-8678-bf2514bb95e9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:#00B050'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Posology</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_81e94759-2110-4cb9-a642-4b8d82f5f9c7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p><em>Adults and adolescents (weighing at least 40kg) </em></p><p>The recommended dose of Triumeq in adults and adolescents is one tablet once daily.</p><p>Triumeq should not be administered to adults or adolescents who weigh less than 40&nbsp;kg because it is a fixed‑dose tablet that cannot be dose reduced.</p><p>Separate preparations of dolutegravir, abacavir or lamivudine are available in cases where discontinuation or dose adjustment of one of the active substances is indicated. In these cases the physician should refer to the individual product information for these medicinal products.</p><p>A separate preparation of dolutegravir is applicable where a dose adjustment is indicated due to drug-drug interactions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&rsquo;s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir (see section <em>Special warnings and precautions for use</em> and <em>Interaction with other medicinal products and other forms of interaction).</em></p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Missed doses</em></p><p>If the patient misses a dose of Triumeq, the patient should take it as soon as possible, providing the next dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.</p><p><em>Elderly</em></p><p>There are limited data available on the use of dolutegravir, abacavir and lamivudine in patients aged 65 years and over. There is no evidence that elderly patients require a different dose than younger adult patients (see section <strong>&nbsp;</strong><em>Pharmacokinetic properties</em>). Special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters.</p><p><em>Renal impairment</em></p><p>Triumeq is not recommended for use in patients with a creatinine clearance &lt;&nbsp;30&nbsp;mL/min (see<em> </em>section<em> Pharmacokinetic properties</em>). No dose adjustment is required in patients with mild or moderate renal impairment. However, the lamivudine exposure is significantly increased in patients with a creatinine clearance &lt; 50 mL/min (see section <em>Special warnings and precautions for use</em>).</p><p><em>Hepatic impairment</em></p><p>Abacavir is primarily metabolised by the liver. No clinical data are available in patients with moderate or severe hepatic impairment, therefore the use of Triumeq is not recommended unless judged necessary. In patients with mild hepatic impairment (Child-Pugh score 5-6) close monitoring is required, including monitoring of abacavir plasma levels if feasible (see sections<em> Special warnings and precautions for use </em>and<em> Pharmacokinetic properties</em>).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Triumeq in children less than 12 years of age has not yet been established. No data are available.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0c5db203-ba95-4238-81fd-eac6d1609d12 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use</p><p>Triumeq can be taken with or without food (see section<em> Pharmacokinetic properties</em>).<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7ad070d6-a8ce-43e8-8454-b005194f4d88 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section List of excipients. See section list of excipients. 

Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter (OCT) 2, including but not limited to fampridine (also known as dalfampridine; see section Interaction with other medicinal products and other forms of interaction).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><em><u>Hypersensitivity reactions (see section</u></em><strong><u> </u></strong><em><u>Undesirable effects</u></em><em><u>)</u></em></p><p>Both abacavir and dolutegravir are associated with a risk for hypersensitivity reactions (HSR) (see section<em> Undesirable effects</em>), and share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement. Clinically it is not possible to determine whether a HSR with Triumeq would be caused by abacavir or dolutegravir. Hypersensitivity reactions have been observed more commonly with abacavir, some of which have been life-threatening, and in rare cases fatal, when not managed appropriately. The risk for abacavir HSR to occur is high for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a low frequency in patients who do not carry this allele. <!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_de926d68-ee70-4bca-a315-958c6141c681 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Therefore, the following should always be adhered to:</p><p>- HLA-B*5701 status must always be documented prior to initiating therapy.</p><p>- Triumeq should never be initiated in patients with a positive HLA-B*5701 status, nor in patients with a negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir-containing regimen.</p><p>- <strong>Triumeq must be stopped without delay</strong>, even in the absence of the HLA-B*5701 allele, if an HSR is suspected. Delay in stopping treatment with Triumeq after the onset of hypersensitivity may result in an immediate and life-threatening reaction. Clinical status including liver aminotransferases and bilirubin should be monitored.</p><p>- After stopping treatment with Triumeq for reasons of a suspected HSR, <strong>Triumeq or any other medicinal product containing abacavir or dolutegravir must never be re-initiated</strong>.</p><p>- Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours. This recurrence is usually more severe than on initial presentation, and may include life-threatening hypotension and death.</p><p>- In order to avoid restarting abacavir and dolutegravir, patients who have experienced a suspected HSR should be instructed to dispose of their remaining Triumeq tablets.<strong> </strong></p><p><em><u>Clinical description of HSRs</u></em></p><p>Hypersensitivity reactions have been reported in &lt;1% of patients treated with dolutegravir in clinical studies, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.</p><p>Abacavir HSR has been well characterised through clinical studies and during post marketing follow-up. Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, <strong>although these reactions may occur at any time during therapy.</strong></p><p>Almost all HSR to abacavir will include fever and/or rash. Other signs and symptoms that have been observed as part of abacavir HSR are described in detail in section <em>Undesirable effects</em> (Description of selected adverse reactions), including respiratory and gastrointestinal symptoms. Importantly, such symptoms <strong>may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. </strong>The symptoms related to this HSR worsen with continued therapy and <strong>can be life- threatening</strong>. These symptoms usually resolve upon discontinuation of abacavir.</p><p>Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see Section <em>&nbsp;Undesirable effects</em> Description of selected adverse reactions).&nbsp; Restarting abacavir in such patients must be done in a setting where medical assistance is readily available.</p></td></tr></tbody></table><p><em>Weight and metabolic parameters</em></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids and weight, there is in some cases evidence for a treatment effect. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><u>Liver disease</u></p><p>The safety and efficacy of Triumeq has not been established in patients with significant underlying liver disorders. Triumeq is not recommended in patients with moderate to severe hepatic impairment (see sections <strong>&nbsp;</strong><em>Posology and method of administration </em>and<em> Pharmacokinetic properties</em>).<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c47b3919-0cea-4805-b187-f96a32a7a1de \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.<em> </em></p><p>&nbsp;</p><p><u>Patients with chronic hepatitis B or C</u></p><p>Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.</p><p>Triumeq includes lamivudine, which is active against hepatitis B. Abacavir and dolutegravir lack such activity. Lamivudine monotherapy is generally not considered an adequate treatment for hepatitis B since the risk for hepatitis B resistance development is high. If Triumeq is used in patients co-infected with hepatitis B an additional antiviral is therefore generally needed. Reference should be made to treatment guidelines.</p><p>If Triumeq is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis.</p><p>&nbsp;</p><p><u>Immune Reactivation Syndrome</u></p><p>In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and <em>Pneumocystis jirovecii</em> pneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated, and treatment instituted when necessary. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy.&nbsp; Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. (See &lsquo;Patients with chronic hepatitis B or C&rsquo; earlier in this section and also see section<em> Undesirable effects</em>).</p><p>&nbsp;</p><p><u>Mitochondrial dysfunction following exposure in utero</u></p><p>Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues, these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia), and metabolic disorders (hyperlactatemia, hyperlipasemia). These reactions have often been transitory. Some late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed <em>in utero</em> to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown aetiology, particularly neurologic findings.&nbsp; These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p>&nbsp;</p><p><u>Cardiovascular events</u></p><p>Although the available data from clinical and observational studies with abacavir show inconsistent results, several studies suggest an increased risk of cardiovascular events (notably myocardial infarction) in patients treated with abacavir. Therefore, when prescribing Triumeq, action should be taken to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). In addition, alternative treatment options to the abacavir containing regimen should be considered when treating patients with a high cardiovascular risk.</p><p>&nbsp;</p><p><u>Osteonecrosis</u></p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, bisphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><u>Opportunistic infections</u></p><p>Patients should be advised that Triumeq or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications<strong> </strong>of HIV infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p>&nbsp;</p><p><u>Administration in subjects with moderate renal impairment</u></p><p>Patients with a creatinine clearance between 30 and 49 mL/min receiving Triumeq may experience a 1.6-to 3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance &ge;50 mL/min. There are no safety data from randomised, controlled trials comparing Triumeq to the individual components in patients with a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. In the original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were associated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations due to neutropenia or anaemia each occurred in &lt;1% of subjects. Other lamivudine-related adverse events (such as gastro-intestinal and hepatic disorders) may occur.</p><p>Patients with a sustained creatinine clearance between 30 and 49 mL/min who receive Triumeq should be monitored for lamivudine-related adverse events, notably hematologic toxicities. If new or worsening neutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is indicated, which cannot be achieved with T&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; riumeq. Triumeq should be discontinued and the individual components should be used to construct the treatment regimen.</p><p>&nbsp;</p><p><u>Drug resistance</u><!--[if supportFields]><u><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9ad2e966-cb2c-4d44-abfe-145feb5f3eea \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>The use of Triumeq is not recommended for patients with integrase inhibitor resistance. This is because the recommended dose of dolutegravir is 50 mg twice daily for patients with resistance to integrase inhibitors and there are insufficient data to recommend a dose of dolutegravir in integrase inhibitor resistant adolescents, children and infants.<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9f1eb2eb-c14c-4c69-9f7d-96fad47933b4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Drug interactions</u><!--[if supportFields]><u><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8ee3a222-8dc1-44fc-9bdb-01bf611aac4a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&rsquo;s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir (see section <em>Interaction with other medicinal products and other forms of interaction).</em></p><p>Triumeq should not be co-administered with polyvalent cation-containing antacids. Triumeq is recommended to be administered 2 hours before or 6 hours after these medicinal products (see section<em> Interaction with other medicinal products and other forms of interaction).</em></p><p>When taken with food, Triumeq and supplements or multivitamins containing calcium, iron or magnesium can be taken at the same time. If Triumeq is administered under fasting conditions, supplements or multivitamins containing calcium, iron or magnesium are recommended to be taken 2 hours after or 6 hours before Triumeq (see section <em>Interaction with other medicinal products and other forms of interaction).</em></p><p>Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control (see section<em> Interaction with other medicinal products and other forms of interaction).</em></p><p>Metformin is eliminated renally and therefore it is of importance to monitor renal function when co-treated with dolutegravir. This combination may increase the risk for lactic acidosis in patients with moderate renal impairment (stage 3a creatinine clearance [CrCl] 45&ndash; 59 mL/min) and a cautious approach is recommended. Reduction of the metformin dose should be highly considered.&nbsp;</p><p>The combination of lamivudine with cladribine is not recommended (see section<em> Interaction with other medicinal products and other forms of interaction).</em></p><p>Triumeq should not be taken with any other medicinal products containing dolutegravir, abacavir, lamivudine or emtricitabine, except where a dose adjustment of dolutegravir is indicated due to drug-drug interactions (see section<strong> </strong><em>Interaction with other medicinal products and other forms of interaction).</em></p><p>&nbsp;</p><p><u>Excipients</u></p><p>Triumeq contains less than 1 mmol sodium (23 mg) per tablet, that is to say is essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Triumeq contains dolutegravir, abacavir and lamivudine, therefore any interactions identified for these individually are relevant to Triumeq. No clinically significant drug interactions are expected between dolutegravir, abacavir and lamivudine.</p><p>&nbsp;</p><p><u>Effect of other medicinal products on the pharmacokinetics of dolutegravir, abacavir and lamivudine</u></p><p>Dolutegravir is eliminated mainly through metabolism by uridine diphosphate glucuronosyl transferase (UGT) 1A1. Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and breast cancer resistance protein<strong><em> </em></strong>(BCRP). Co-administration of Triumeq and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration. Medicinal products that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1).</p><p>The absorption of dolutegravir is reduced by certain anti-acid medicinal products (see Table 1).</p><p>Abacavir is metabolised by UGT (UGT2B7) and alcohol dehydrogenase; co-administration of inducers (e.g. rifampicin, carbamazepine and phenytoin) or inhibitors (e.g. valproic acid) of UGT enzymes or with compounds eliminated through alcohol dehydrogenase could alter abacavir exposure.</p><p>Lamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through the OCT 2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an inhibitor of these drug transporters) has been shown to increase lamivudine plasma concentrations, however the resulting increase was not clinically significant (see Table 1).&nbsp; Dolutegravir is an OCT2 and MATE1 inhibitor; however, lamivudine concentrations were similar with or without co-administration of dolutegravir based on a cross study analysis, indicating that dolutegravir has no effect on lamivudine exposure <em>in vivo</em>. Lamivudine is also substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance.</p><p>Although abacavir and lamivudine are substrates of BCRP and P-gp <em>in vitro</em>, given the high absolute bioavailability of abacavir and lamivudine, (see section <em>Pharmacokinetic properties</em>), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on abacavir or lamivudine concentrations.</p><p>&nbsp;</p><p><u>Effect of dolutegravir, abacavir and lamivudine on the pharmacokinetics of other medicinal products</u><!--[if supportFields]><u><span lang=X-NONE
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a855afcc-902b-41d7-8a1a-0678b6a24b8f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p><em>In vivo</em>, dolutegravir did not have an effect on midazolam, a CYP3A4 probe. Based on <em>in vivo </em>and/or <em>in vitro</em> data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section <em>Pharmacokinetic properties</em>).</p><p><em>In vitro</em>, dolutegravir inhibited the renal transporters OCT2 and MATE1. <em>In vivo</em>, a 10-14% decrease of creatinine clearance (secretory fraction is dependent on OCT2 and MATE1 transport) was observed in patients. <em>In vivo</em>, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 and/or MATE1 (e.g. fampridine [also known as dalfampridine], metformin) (see Table 1).</p><p><em>In vitro</em>, dolutegravir inhibited the renal uptake organic anion transporters (OAT)1 and OAT3. Based on the lack of effect on the<em> in vivo</em> pharmacokinetics of the OAT substrate tenofovir, <em>in vivo</em> inhibition of OAT1 is unlikely. Inhibition of OAT3 has not been studied <em>in vivo</em>. Dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OAT3.&nbsp;</p><p><em>In vitro</em>, abacavir demonstrated the potential to inhibit CYP1A1 and limited potential to inhibit metabolism mediated by CYP3A4. Abacavir was an inhibitor of MATE1; the clinical consequences are not known.</p><p><em>In vitro,</em> lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known.</p><p>Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in Table 1.</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interactions between dolutegravir, abacavir, lamivudine and co-administered medical products are listed in Table 1 (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;, area under the concentration versus time curve as &ldquo;AUC&rdquo;, maximum observed concentration as &ldquo;C<sub>max</sub>&rdquo;, concentration at end of dosing interval as &ldquo;C&tau;&rdquo;). The table should not be considered exhaustive but is representative of the classes studied.</p><p>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug interactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Interaction geometric mean change (%) </strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiretroviral medicinal products</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Non-nucleoside reverse transcriptase inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p>Etravirine without boosted protease inhibitors / Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 71%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 52%<br />&nbsp;&nbsp; Ct &macr; 88%<br />&nbsp;</p><p>Etravirine &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration. The recommended dose of dolutegravir is 50 mg twice daily for patients taking etravirine without boosted protease inhibitors. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the etravirine without boosted protease inhibitor co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see section &nbsp;<em>&nbsp;Posology and method of administration</em>).</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir+ritonavir+etravirine/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 11%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 7%<br />&nbsp;&nbsp; Ct &shy; 28%</p><p>&nbsp;</p><p>Lopinavir &laquo;<br />Ritonavir &laquo;<br />Etravirine &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir+ritonavir+etravirine/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 25%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 12%<br />&nbsp;&nbsp; Ct &macr; 36%</p><p>&nbsp;</p><p>Darunavir &laquo;<br />Ritonavir &laquo;<br />Etravirine &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 57%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 39%<br />&nbsp;&nbsp; Ct &macr; 75%<br />&nbsp;</p><p>Efavirenz &laquo; (historical controls)</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The recommended dose of dolutegravir is 50 mg twice daily when co-administered with efavirenz. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the efavirenz co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see section <em>Posology and method of administration).</em></p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction)</p></td><td style="vertical-align:top"><p>Co-administration with nevirapine may decrease dolutegravir plasma concentration due to enzyme induction and has not been studied. Effect of nevirapine on dolutegravir exposure is likely similar to or less than that of efavirenz. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with nevirapine. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the nevirapine co-administration &nbsp;(a separate preparation of dolutegravir is available for this dose adjustment, see<strong> </strong>section<em> Posology and method of administration</em>).</p></td></tr><tr><td style="vertical-align:top"><p>Rilpivirine</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 12%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 13%</p><p>&nbsp;&nbsp; C&tau; &shy; 22%</p><p>Rilpivirine &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nucleoside reverse transcriptase inhibitors (NRTIs)</em></p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Emtricitabine, didanosine, stavudine, zidovudine.</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 1%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 3%</p><p>&nbsp;&nbsp; C&tau;&nbsp; &macr; 8%</p><p>Tenofovir &laquo;</p><p>&nbsp;</p><p>Interaction not studied</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary when Triumeq is combined with nucleoside reverse transcript inhibitors.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Triumeq is not recommended for use in combination with emtricitabine containing products, since both lamivudine (in Triumeq) and emtricitabine are cytidine analogues (i.e. risk for intracellular interactions, (see section <em>Special warnings and precautions for use</em>)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Protease inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 91%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 50%<br />&nbsp;&nbsp; Ct &shy; 180%<br />&nbsp;</p><p>Atazanavir &laquo; (historical controls)</p><p>(inhibition of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir+ ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 62%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 34%<br />&nbsp;&nbsp; Ct &shy; 121%<br />&nbsp;</p><p>Atazanavir &laquo;<br />Ritonavir &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 59%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 47%<br />&nbsp;&nbsp; Ct &macr; 76%<br />&nbsp;</p><p>Tipranavir &laquo;<br />Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The recommended dose of dolutegravir is 50 mg twice daily when co-administered with tipranavir/ritonavir. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the tipranavir/ritonavir co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see<strong> </strong>section<strong> </strong><em>Posology and method of administration</em>).</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir&macr;<br />&nbsp;&nbsp; AUC &macr; 35%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 24%<br />&nbsp;&nbsp; Ct &macr; 49%<br />&nbsp;</p><p>Fosamprenavir&laquo;</p><p>Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies. No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir+ritonavir/<br />Dolutegravir<br /><br />&nbsp;</p><p>&nbsp;</p><p><br /><br /><br />Lopinavir+ritonavir/<br />Abacavir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC&nbsp; &macr; 4%<br />&nbsp;&nbsp; C<sub>max</sub> &laquo; 0%<br />&nbsp;&nbsp; C<sub>24</sub>&macr; 6%</p><p>&nbsp;</p><p>Lopinavir &laquo;<br />Ritonavir &laquo;<br /><br />Abacavir&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AUC &darr; 32%</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 22%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%<br />&nbsp;&nbsp; Ct &macr; 38%</p><p>&nbsp;</p><p>Darunavir &laquo;<br />Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Other antiviral agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>Daclatasvir/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 33%<br />&nbsp;&nbsp; C<sub>max </sub>&shy; 29%<br />&nbsp;&nbsp; Ct &shy; 45%</p><p>Daclatasvir &laquo;</p></td><td style="vertical-align:top"><p>Daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent.&nbsp; Dolutegravir did not change daclatasvir plasma concentration. No dose adjustment is necessary.</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-infective products</strong></p></td></tr><tr><td style="vertical-align:top"><p>Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Abacavir</p><p>&nbsp;</p><p>Trimethoprim/sulfamethoxazole</p><p>(Co-trimoxazole)/Lamivudine</p><p>(160mg/800mg once daily for 5 days/300mg single dose)</p></td><td style="vertical-align:top"><p>Interaction not studied</p><p>&nbsp;</p><p>&nbsp;</p><p>Lamivudine:</p><p>&nbsp;&nbsp; AUC &shy;43%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy;7%</p><p>&nbsp;</p><p>Trimethoprim:</p><p>&nbsp;&nbsp; AUC &laquo;</p><p>&nbsp;</p><p>Sulfamethoxazole:</p><p>&nbsp;&nbsp; AUC &laquo;</p><p>&nbsp;</p><p>(organic cation transporter inhibition)</p></td><td style="vertical-align:top"><p>No Triumeq dose adjustment necessary, unless patient has renal impairment (See section <em>Posology and method of administration</em>).</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antimycobacterials</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 43%<br />&nbsp;&nbsp; Ct &macr; 72%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>The dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the rifampicin co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see section <em>Posology and method of administration</em>).</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &macr; 5%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 16%<br />&nbsp;&nbsp; C&tau; &macr; 30%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anticonvulsants</strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 49%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 33%<br />&nbsp;&nbsp; Ct &macr; 73%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>The recommended dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the carbamazepine co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see <em>Posology and method of administration</em>).</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital/Dolutegravir</p><p>Phenytoin/Dolutegravir</p><p>Oxcarbazepine/Dolutegravir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir&macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)</p></td><td style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with these metabolic inducers. As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the co-administration with these metabolic inducers (a separate preparation of dolutegravir is available for this dose adjustment, see section <em>Posology and method of administration</em>).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antihistamines (histamine H2 receptor antagonists)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.</p></td><td style="vertical-align:top"><p>No dose adjustment necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.</p></td><td style="vertical-align:top"><p>No dose adjustment necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cytotoxics</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cladribine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p><em>In vitro</em> lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine</p></td><td style="vertical-align:top"><p>Concomitant use of Triumeq with cladribine is not recommended (see section <em>Special warnings and precautions for use</em>).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Opioids</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methadone/Abacavir</p><p>(40 to 90mg once daily for 14 days/600mg single dose, then 600mg twice daily for 14 days)</p></td><td style="vertical-align:top"><p>Abacavir:&nbsp;</p><p>&nbsp;&nbsp; AUC &laquo;</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr;35%</p><p>&nbsp;</p><p>Methadone:</p><p>&nbsp;&nbsp; CL/F &shy;22%</p></td><td style="vertical-align:top"><p>Methadone dose adjustment likely not needed in majority of patients; occasionally methadone re-titration may be required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Retinoids</strong></p></td></tr><tr><td style="vertical-align:top"><p>Retinoid compounds<br />(e.g. Isotretinoin)</p></td><td style="vertical-align:top"><p>Interaction not studied</p><p>&nbsp;</p><p>Possible interaction given common pathway of elimination via alcohol dehydrogenase (abacavir-component).</p></td><td style="vertical-align:top"><p>Insufficient data to recommend dose adjustment.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Miscellaneous</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Alcohol</em></p></td></tr><tr><td style="vertical-align:top"><p>Ethanol/Dolutegravir</p><p>Ethanol/Lamivudine</p><p>&nbsp;</p><p>&nbsp;</p><p>Ethanol/Abacavir</p><p>(0.7 g/kg single dose/600mg single dose)</p></td><td style="vertical-align:top"><p>Interaction not studied (Inhibition of alcohol dehydrogenase)</p><p>&nbsp;</p><p>Abacavir:</p><p>&nbsp;&nbsp; AUC &shy; 41%</p><p>Ethanol:</p><p>&nbsp;&nbsp; AUC &laquo;</p></td><td style="vertical-align:top"><p>No dose adjustment necessary.</p></td></tr><tr><td style="vertical-align:top"><p><em>Sorbitol</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sorbitol solution (3.2 g, 10.2&nbsp;g, 13.4&nbsp;g)/Lamivudine</p></td><td style="vertical-align:top"><p>Single dose lamivudine oral solution 300 mg</p><p>Lamivudine:</p><p>AUC &macr; 14%; 32%; 36%</p><p>C<sub>max</sub> &macr; 28%; 52%, 55%.</p></td><td style="vertical-align:top"><p>When possible, avoid chronic coadministration of Triumeq with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (eg: xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Potassium channel blockers</em></p></td></tr><tr><td style="vertical-align:top"><p>Fampridine (also known as dalfampridine)/Dolutegravir</p></td><td style="vertical-align:top"><p>Fampridine &shy;<br />&nbsp;</p></td><td style="vertical-align:top"><p>Co-administration of dolutegravir has the potential to cause seizures due to increased fampridine plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co-administration with Triumeq is contraindicated (see section<strong> </strong><em>Contraindications</em>).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antacids and supplements</em></p></td></tr><tr><td style="vertical-align:top"><p>Magnesium/</p><p>aluminium‑containing antacids/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />AUC &macr; 74%<br />C<sub>max</sub> &macr; 72%<br />&nbsp;</p><p>(Complex binding to polyvalent ions)</p></td><td style="vertical-align:top"><p>Magnesium/ aluminium-containing antacids should be taken well separated in time from the administration of Triumeq (minimum 2 hours after or 6 hours before the intake of Triumeq).</p></td></tr><tr><td style="vertical-align:top"><p>Calcium supplements/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 39%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 37%<br />&nbsp; C<sub>24</sub>&macr; 39%</p><p>(Complex binding to polyvalent ions)</p></td><td rowspan="3" style="vertical-align:top"><p>- When taken with food, Triumeq and supplements or multivitamins containing calcium, iron or magnesium can be taken at the same time.</p><p>- If Triumeq is taken in a fasted state, such supplements should be taken a minimum 2 hours after or 6 hours before the intake of Triumeq.</p><p>&nbsp;</p><p>The stated reductions in dolutegravir exposure were observed with the intake of dolutegravir and these supplements during fasted conditions. In fed state, the changes in exposure following intake together with calcium or iron supplements were modified by the food effect, resulting in an exposure similar to that obtained with dolutegravir administered in the fasted state.</p></td></tr><tr><td style="vertical-align:top"><p>Iron supplements/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 57%<br />&nbsp;&nbsp; C<sub>2</sub><sub>4</sub>&macr; 56%</p><p>(Complex binding to polyvalent ions)</p></td></tr><tr><td style="vertical-align:top"><p>Multivitamins (containing calcium, iron and magnesium) /Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>&nbsp;&nbsp; AUC &macr; 33%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 35%</p><p>&nbsp;&nbsp; C<sub>2</sub><sub>4</sub>&macr; 32%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Corticosteroids</em></p></td></tr><tr><td style="vertical-align:top"><p>Prednisone</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 11%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 6%</p><p>&nbsp;&nbsp; C&tau; &shy; 17%</p></td><td style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antidiabetics</em></p></td></tr><tr><td style="vertical-align:top"><p>Metformin/Dolutegravir</p></td><td style="vertical-align:top"><p>Metformin &shy;</p><p>Dolutegravir &laquo;</p><p>When co-administered with dolutegravir 50mg QD:</p><p>Metformin<br />&nbsp;&nbsp; AUC &shy; 79%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 66%</p><p>When co-administered with dolutegravir 50mg BID:</p><p>&nbsp;&nbsp; Metformin<br />&nbsp;&nbsp; AUC &shy; 145 %<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 111%</p></td><td style="vertical-align:top"><p>A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control. In patients with moderate renal impairment a dose adjustment of metformin should be considered when coadministered with dolutegravir, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration (section<em> Special warnings and precautions for use</em>).</p></td></tr><tr><td style="vertical-align:top"><p><em>Herbal products</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort/Dolutegravir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir&macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)</p></td><td style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with St. John&rsquo;s wort, As Triumeq is a fixed dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the St John&rsquo;s wort co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see section <em>Posology and method of administration</em>).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Oral contraceptives</em></p></td></tr><tr><td style="vertical-align:top"><p>Ethinyl estradiol (EE) and Norgestromin (NGMN)/Dolutegravir</p></td><td style="vertical-align:top"><p>Effect of dolutegravir:</p><p>EE &laquo;<br />&nbsp;&nbsp; AUC &shy; 3%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 1%<br />&nbsp;</p><p>Effect of dolutegravir:</p><p>NGMN &laquo;<br />&nbsp;&nbsp; AUC &macr; 2%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%</p></td><td style="vertical-align:top"><p>Dolutegravir had no Pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with Triumeq.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antihypertensive</em></p></td></tr><tr><td style="vertical-align:top"><p>Riociguat/Abacavir</p></td><td style="vertical-align:top"><p>Riociguat &shy; &shy;</p><p><em>In vitro</em>, abacavir inhibits CYP1A1. Concomitant administration of a single dose of riociguat (0.5 mg) to HIV patients receiving Triumeq led to an approximately three-fold higher riociguat AUC<sub>(0-&infin;)</sub> when compared to historical riociguat AUC<sub>(0-&infin;)</sub> reported in healthy subjects.</p></td><td style="vertical-align:top"><p>Riociguat dose may need to be reduced, consult the riociguat prescribing information for dosing recommendations.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of childbearing potential should be counselled about the potential risk of neural tube defects with dolutegravir (a component of Triumeq, see below), including consideration of effective contraceptive measures.</p><p>If a woman plans pregnancy, the benefits and the risks of continuing treatment with Triumeq should be discussed with the patient.</p><p>&nbsp;</p><p><u>Pregnancy </u></p><p>Human experience from a birth outcome surveillance study in Botswana shows a small increase of neural tube defects; 7 cases in 3,591 deliveries (0.19%; 95% CI 0.09%, 0.40%) to mothers taking dolutegravir-containing regimens at the time of conception compared to 21 cases in 19,361 deliveries (0.11%: 95% CI 0.07%, 0.17%) to women exposed to non-dolutegravir regimens at the time of conception.</p><p>The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%). Most neural tube defects occur within the first 4 weeks of embryonic development after conception (approximately 6 weeks after the last menstrual period). If a pregnancy is confirmed in the first trimester while on Triumeq, the benefits and risks of continuing Triumeq versus switching to another antiretroviral regimen should be discussed with the patient taking the gestational age and the critical time period of neural tube defect development into account.</p><p>Data analysed from the Antiretroviral Pregnancy Registry do not indicate an increased risk of major birth defects in over 600 women exposed to dolutegravir during pregnancy but are currently insufficient to address the risk of neural tube defects.</p><p>In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including neural tube defects, were identified (see section<em> Preclinical safety data</em>).</p><p>More than 1000 outcomes from exposure to dolutegravir during second and third trimester pregnancy indicate no evidence of increased risk of foetal/neonatal toxicity. Triumeq may be used during the second and third trimester of pregnancy when the expected benefit justifies the potential risk to the foetus.</p><p>Dolutegravir crosses the placenta in humans. In pregnant women living with HIV, the median foetal umbilical cord concentration of dolutegravir was approximately 1.3-fold greater compared with the maternal peripheral plasma concentration.</p><p>There is insufficient information on the effects of dolutegravir on neonates.</p><p>Concerning lamivudine, a large amount of data (more than 5200 outcomes from first trimester) indicates no malformative toxicity. A moderate amount of data (more than 1200 outcomes from first trimester) indicates no malformative toxicity for abacavir.</p><p>Abacavir and lamivudine may inhibit cellular DNA replication and abacavir has been shown to be carcinogenic in animal models (see section<em> Preclinical safety data</em>). The clinical relevance of these findings is unknown.</p><p><em>Mitochondrial dysfunction</em></p><p>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues (see section <em>Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><u>Breast-feeding</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>Dolutegravir is excreted in human milk in small amounts. (a median dolutegravir breast milk to maternal plasma ratio of 0.033 has been shown). There is insufficient information on the effects of dolutegravir in neonates/infants.</p><p>Abacavir and its metabolites are excreted into the milk of lactating rats. Abacavir is also excreted into human milk.</p><p>Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age. There are no data available on the safety of abacavir and lamivudine when administered to babies less than three months old.</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><u>Fertility</u><!--[if supportFields]><u><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>There are no data on the effects of dolutegravir, abacavir or lamivudine on human male or female fertility. Animal studies indicate no effects of dolutegravir, abacavir or lamivudine on male or female fertility (see section<em> Preclinical safety data</em>). &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Triumeq has no or negligible influence on the ability to drive and use machines. Patients should be informed that dizziness has been reported during treatment with dolutegravir. The clinical status of the patient and the adverse reaction profile of Triumeq should be borne in mind when considering the patient&rsquo;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>The most frequently reported adverse reactions related to dolutegravir and abacavir/lamivudine were nausea (12%), insomnia (7%), dizziness (6%) and headache (6%).</p><p>Many of the adverse reactions listed in the table below occur commonly (nausea, vomiting, diarrhoea, fever, lethargy, rash) in patients with abacavir hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity (see section <em>Special warnings and precautions for use</em>). Very rarely cases of erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported where abacavir hypersensitivity could not be ruled out. In such cases medicinal products containing abacavir should be permanently discontinued.</p><p>The most severe adverse reaction related to the treatment with dolutegravir and abacavir/lamivudine, seen in individual patients, was a hypersensitivity reaction that included rash and severe liver effects (see section <em>Special warnings and precautions for use</em> and Description of selected adverse reactions in this section).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions with the components of Triumeq from clinical study and post-marketing experience are listed in Table 2 by body system, organ class and absolute frequency. Frequencies are defined as very common (&sup3;&nbsp;1/10), common (&sup3;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&sup3;&nbsp;1/1000 to &lt;&nbsp;1/100), rare (&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1000), very rare (&lt;&nbsp;1/10,000).</p><p>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of adverse reactions associated with the combination of dolutegravir + abacavir/lamivudine in an analysis of pooled data from: Phase IIb to Phase IIIb clinical studies or post-marketing experience; and adverse reactions to treatment with dolutegravir, abacavir and lamivudine from clinical studies and post-marketing experience when used with other antiretrovirals</p><table border="1" cellspacing="0" cellpadding="0" style="width:535px"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Blood and lymphatic systems disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Neutropenia<sup>1</sup>, anaemia<sup>1</sup>, thrombocytopenia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>pure red cell aplasia<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>hypersensitivity (see section <em>Special warnings and precautions for use</em>)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>immune reconstitution syndrome (see section<em> Special warnings and precautions for use</em>)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>anorexia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>hypertriglyceridaemia, hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>lactic acidosis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Psychiatric disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>abnormal dreams, depression, anxiety<sup>1</sup>, nightmare, sleep disorder</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>suicidal ideation or suicide attempt (particularly in patients with a pre-existing history of depression or psychiatric illness), panic attack</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>completed suicide (particularly in patients with a pre-existing history of depression or psychiatric illness)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>dizziness, somnolence, lethargy<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>peripheral neuropathy<sup>1</sup>, paraesthesia<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>cough<sup>1</sup>, nasal symptoms<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>nausea, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>vomiting, flatulence, abdominal pain, abdominal pain upper, abdominal distension, abdominal discomfort, gastro-oesophageal reflux disease, dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>pancreatitis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>acute hepatic failure<sup>1</sup>, increased bilirubin<sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>rash, pruritus, alopecia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>erythema multiform<sup>1</sup>, Stevens-Johnson syndrome<sup>1</sup>, toxic epidermal necrolysis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Arthralgia<sup>1</sup>, muscle disorders<sup>1</sup>(including myalgia<sup>1</sup>)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>rhabdomyolysis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>asthenia, fever<sup>1</sup>, malaise<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Investigations:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>CPK elevations, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>amylase elevations<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>This adverse reaction was identified from clinical studies or post-marketing experience for dolutegravir, abacavir or lamivudine when used with other antiretrovirals or post-marketing experience with Triumeq.</p><p><sup>2</sup>In combination with increased transaminases.</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em>Hypersensitivity reactions</em></p><p>Both abacavir and dolutegravir are associated with a risk for hypersensitivity reactions (HSR), which were observed more commonly with abacavir. Hypersensitivity reaction observed for each of these medicinal products (described below) share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement. Time to onset was typically 10-14 days for both abacavir and dolutegravir-associated reactions, although reactions to abacavir may occur at any time during therapy. Treatment with Triumeq must be stopped without delay if HSR cannot be ruled out on clinical grounds, and therapy with Triumeq or other abacavir or dolutegravir containing products must never be re-initiated. Please refer to section <em>Special warnings and precautions for use</em> for further details on patient management in the event of a suspected HSR to Triumeq.</p><p><em><u>Dolutegravir hypersensitivity</u></em></p><p>Symptoms have included rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em><u>Abacavir hypersensitivity</u></em></p><p>The signs and symptoms of this HSR are listed below. These have been identified either from clinical studies or post marketing surveillance. Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.</p><p>Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.</p></td></tr><tr><td style="vertical-align:top"><p>Skin</p></td><td style="vertical-align:top"><p><strong>Rash </strong>(usually maculopapular or urticarial)</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal tract</em></p></td><td style="vertical-align:top"><p><strong>Nausea, vomiting, diarrhoea, abdominal pain</strong>, mouth ulceration</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory tract</em></p></td><td style="vertical-align:top"><p><strong>Dyspnoea,</strong> <strong>cough</strong>, sore throat, adult respiratory distress syndrome, respiratory failure</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Miscellaneous</em></p></td><td style="vertical-align:top"><p><strong>Fever, lethargy, malaise</strong>, oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Neurological/Psychiatry</em></p></td><td style="vertical-align:top"><p><strong>Headache</strong>, paraesthesia</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haematological</em></p></td><td style="vertical-align:top"><p>Lymphopenia</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Liver/pancreas</em></p></td><td style="vertical-align:top"><p><strong>Elevated liver function tests, </strong>hepatitis, hepatic failure</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal</em></p></td><td style="vertical-align:top"><p><strong>Myalgia</strong>, rarely myolysis, arthralgia, elevated creatine phosphokinase</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Urology</em></p></td><td style="vertical-align:top"><p>Elevated creatinine, renal failure</p><p>&nbsp;</p></td></tr></tbody></table><p>Symptoms related to this HSR worsen with continued therapy and can be life-threatening and in rare instance, have been fatal.</p><p>Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours. This recurrence of the HSR is usually more severe than on initial presentation and may include life-threatening hypotension and death.<strong> </strong>Similar reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).</p><p><em>&nbsp;</em></p><p><em>Metabolic parameters</em></p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section<em> </em><em>Special warnings and precautions for use</em>)</p><p>&nbsp;</p><p><em>Osteonecrosis</em></p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section<em> Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><em>Immune reactivation syndrome </em></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section<em> Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><u>Changes in laboratory chemistries</u></p><p>Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 96 weeks. In the SINGLE study a mean change from baseline of 12.6&nbsp;mmol/L was observed after 96 weeks of treatment. These changes are not considered to be clinically relevant since they do not reflect a change in glomerular filtration rate.</p><p>Asymptomatic creatine phosphokinase (CPK) elevations mainly in association with exercise have also been reported with dolutegravir therapy.</p><p>&nbsp;</p><p><u>Co-infection with Hepatitis B or C</u></p><p>In dolutegravir Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There are no clinical study data on the effects of Triumeq in the paediatric population. Individual components have been investigated in adolescents (12 to 17 years).</p><p>Based on limited available data with the dolutegravir single entity used in combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional types of adverse reactions beyond those observed in the adult population.</p><p>The individual preparations of abacavir and lamivudine have been investigated separately, and as a dual nucleoside backbone, in combination antiretroviral therapy to treat ART- naive and ART- experienced HIV- infected paediatric patients (data available on the use of abacavir and lamivudine in infants less than three months are limited).&nbsp; No additional types of adverse reactions have been observed beyond those characterised for the adult population.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: 21T npc.drug@sfda.gov.sa</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Website: 21T21Thttps://ade.sfda.gov.sa21T</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: 21T21Tsaudi.safety@gsk.com21T21T<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: 21T21Thttps://gskpro.com/en-sa/21T21T<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: 21T21Tgcc.medinfo@gsk.com21T21T&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: 21T21Thttps://gskpro.com/en-sa/ 21T21&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific symptoms or signs have been identified following acute overdose with dolutegravir, abacavir or lamivudine, apart from those listed as adverse reactions.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.&nbsp; There is no specific treatment for an overdose of Triumeq. If overdose occurs, the patient should be treated supportively with appropriate monitoring, as necessary. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infections, combinations. ATC code: J05AR13</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.</p><p>Abacavir and lamivudine are potent selective inhibitors of HIV-1 and HIV-2. Both abacavir and lamivudine are metabolised sequentially by intracellular kinases to the respective 5&#39;-triphosphates (TP) which are the active moieties with extended intracellular half-lives supporting once daily dosing (see section <em>Pharmacokinetic properties</em>). Lamivudine-TP (an analogue for cytidine) and carbovir-TP (the active triphosphate form of abacavir, an analogue for guanosine) are substrates for and competitive inhibitors of HIV reverse transcriptase (RT). However, their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. Abacavir and lamivudine triphosphates show significantly less affinity for host cell DNA polymerases.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>Antiviral activity in vitro</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b1d5e894-d4b3-4a33-a860-4547d07b204f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>Dolutegravir, abacavir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages. The concentration of active substance necessary to effect viral replication by 50% (IC50 - half maximal inhibitory concentration) varied according to virus and host cell type.</p><p>The IC<sub>50</sub> for dolutegravir in various lab-strains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM. Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14). The mean IC50 for 3 HIV-2 isolates was 0.18 nM (range 0.09-0.61).</p><p>The mean IC<sub>50</sub> for abacavir against lab-strains of HIV-1IIIB and HIV‑1HXB2 ranged from 1.4 to 5.8&nbsp;mM. The median or mean IC50 values for lamivudine against lab-strains of HIV-1 ranged from 0.007 to 2.3&nbsp;mM. The mean IC<sub>50</sub> against lab-strains of HIV-2 (LAV2 and EHO) ranged from 1.57 to 7.5&nbsp;mM for abacavir and from 0.16 to 0.51&nbsp;mM for lamivudine.</p><p>The IC50 values of abacavir against HIV-1 Group M subtypes (A-G) ranged from 0.002 to 1.179&nbsp;mM, against Group O from 0.022 to 1.21&nbsp;mM, and against HIV-2 isolates, from 0.024 to 0.49&nbsp;mM. For lamivudine, the IC50 values against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170&nbsp;mM, against Group O from 0.030 to 0.160&nbsp;mM and against HIV-2 isolates from 0.002 to 0.120&nbsp;mM in peripheral blood mononuclear cells.</p><p>HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC50 fold changes &lt; 2.5), and lamivudine (IC50 fold changes &lt; 3.0), except for two CRF02_AG isolates with fold changes of 2.9 and 3.4 for abacavir.&nbsp; Group O isolates from antiviral na&iuml;ve patients tested for lamivudine activity were highly sensitive.</p><p>The combination of abacavir and lamivudine has demonstrated antiviral activity in cell culture against non-subtype B isolates and HIV-2 isolates with equivalent antiviral activity as for subtype B isolates.</p><p>&nbsp;</p><p><em>Antiviral activity in combination with other antiviral agents</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b1ab690c-13eb-4eb2-946f-015fb10db76e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>No antagonistic effects <em>in vitro</em> were seen with dolutegravir and other antiretrovirals (tested agents: stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, maraviroc, adefovir and raltegravir).&nbsp; In addition, ribavirin had no apparent effect on dolutegravir activity.&nbsp;</p><p>The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.</p><p>No antagonistic effects <em>in vitro </em>were seen with lamivudine and other antiretrovirals (tested agents: abacavir, didanosine, nevirapine, zalcitabine, and zidovudine).</p><p><em>&nbsp;</em></p><p><em>Effect of human serum</em><!--[if supportFields]><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9a107793-acf2-49f0-b7d9-71d7b8d2d084 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>In 100% human serum, the mean fold shift for dolutegravir activity was 75-fold, resulting in protein adjusted IC90 of 0.064 ug/mL. Plasma protein binding studies <em>in vitro</em> indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.&nbsp; Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding (less than 36%).</p><p>&nbsp;</p><p><u>Resistance</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_aa1ba298-661e-43cd-9678-c41eac53b8b2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p><em>Resistance in vitro</em>: <em>(dolutegravir)</em><!--[if supportFields]><i><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_344508f5-bcf1-411b-8e75-e9c922552057 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Serial passage is used to study resistance evolution <em>in vitro</em>. When using the lab-strain HIVIII during passage over 112 days, mutations selected appeared slowly, with substitutions at positions S153Y and F. These mutations were not selected in patients treated with dolutegravir in the clinical studies.&nbsp; Using strain NL432 mutations E92Q (fold change 3) and G193E (fold change 3) were selected. These mutations have been selected in patients with pre-existing raltegravir resistance and who were then treated with dolutegravir (listed as secondary mutations for dolutegravir).</p><p>In further selection experiments using clinical isolates of subtype B, mutation R263K was seen in all five isolates (after 20 weeks and onwards). In subtype C (n=2) and A/G (n=2) isolates the integrase substitution R263K was selected in one isolate, and G118R in two isolates.&nbsp; R263K was reported from two individual patients with subtype B and subtype C in the clinical program for ART experienced, INI naive subjects, but without effects on dolutegravir susceptibility <em>in vitro</em>. G118R lowers the susceptibility to dolutegravir in site directed mutants (fold change 10), but was not detected in patients receiving dolutegravir in the Phase III program.&nbsp;</p><p>Primary mutations for raltegravir/elvitegravir (Q148H/R/K, N155H, Y143R/H/C, E92Q, T66I) do not affect the <em>in vitro</em> susceptibility of dolutegravir as single mutations. When mutations listed as secondary integrase inhibitor associated mutations (for raltegravir/elvitegravir) are added to primary mutations (excluding at Q148) in experiments with site directed mutants, dolutegravir susceptibility remains at or near wildtype level.&nbsp; In the case of the Q148-mutation viruses, increasing dolutegravir fold change is seen as the number of secondary mutations increase. The effect of the Q148-based mutations (H/R/K) was also consistent with <em>in vitro</em> passage experiments with site directed mutants.&nbsp; In serial passage with strain NL432-based site directed mutants at N155H or E92Q, no further selection of resistance was seen (fold change unchanged around 1). In contrast, starting passage with mutants with mutation Q148H (fold change 1), a variety of raltegravir associated secondary mutations accumulated with a consequent increase of fold change to values &gt;10.</p><p>A clinically relevant phenotypic cut-off value (fold change vs wild type virus) has not been determined; genotypic resistance was a better predictor for outcome.</p><p>Seven hundred and five raltegravir resistant isolates from raltegravir experienced patients were analyzed for susceptibility to dolutegravir.&nbsp; Dolutegravir has a &lt;10-fold change against 94% of the 705 clinical isolates.</p><p>&nbsp;</p><p><em>Resistance in vivo: (dolutegravir)</em></p><p>In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=876, follow-up of 48-96 weeks).</p><p>In patients with prior failed therapies, but na&iuml;ve to the integrase class (SAILING study), integrase inhibitor substitutions were observed in 4/354 patients (follow-up 48 weeks) treated with dolutegravir, which was given in combination with an investigator selected background regimen (BR). Of these four, two subjects had a unique R263K integrase substitution, with a maximum fold change of 1.93, one subject had a polymorphic V151V/I integrase substitution, with maximum fold change of 0.92, and one subject had pre-existing integrase mutations and is assumed to have been integrase experienced or infected with integrase resistant virus by transmission. The R263K mutation was also selected <em>in vitro</em> (see above).</p><p>&nbsp;</p><p><em>Resistance in vitro and in vivo: (abacavir and lamivudine)</em></p><p>Abacavir-resistant isolates of HIV-1 have been selected <em>in vitro</em> and<em> in vivo </em>and are associated with specific genotypic changes in the RT codon region (codons M184V, K65R, L74V and Y115F). During <em>in vitro</em> abacavir selection the M184V mutation occurred first and resulted in about a 2-fold increase in IC50, below the abacavir clinical cut-off of 4.5-fold change.&nbsp; Continued passage in increasing concentrations of drug resulted in selection for double RT mutants 65R/184V and 74V/184V or triple RT mutant 74V/115Y/184V. Two mutations conferred a 7 to 8-fold change in abacavir susceptibility and combinations of three mutations were required to confer more than an 8-fold change in susceptibility.</p><p>HIV-1 resistance to lamivudine involves the development of a M184I or M184V amino acid change close to the active site of the viral RT. This variant arises both <em>in vitro</em> and in HIV-1 infected patients treated with lamivudine-containing antiretroviral therapy.&nbsp; M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity <em>in vitro</em>. M184V is associated with about a 2-fold increase in abacavir resistance but does not confer clinical resistance for abacavir.</p><p>Isolates resistant to abacavir may also show reduced sensitivity to lamivudine.&nbsp; The combination of abacavir/lamivudine has demonstrated decreased susceptibility to viruses with the substitutions K65R with or without the M184V/I substitution, and to viruses with L74V plus the M184V/I substitution.</p><p>Cross-resistance between dolutegravir or abacavir or lamivudine and antiretrovirals from other classes e.g. PIs or NNRTIs is unlikely.</p><p>&nbsp;</p><p><u>Effects on electrocardiogram</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_97d48485-118c-4abf-b2b3-fa0ce1719a3f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>No relevant effects were seen on the QTc interval, with doses of dolutegravir exceeding the clinical dose by approximately 3-fold. &nbsp;Similar studies were not conducted with either abacavir or lamivudine.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy of Triumeq in HIV-infected, therapy naive subjects is based on the analyses of data from a number of trials. The analyses included two &nbsp;randomised, international, double-blind, active-controlled trials, SINGLE (ING114467) and SPRING-2 (ING113086), the international, open-label, active-controlled trial FLAMINGO (ING114915), and the randomised, open-label, active-controlled, multicenter , non-inferiority study ARIA (ING117172).</p><p>The STRIIVING study (201147), was a &nbsp;randomised, open-label, active-controlled, &nbsp;multicenter, non-inferiority switch study in virologically suppressed subjects with no documented history of resistance to any class.</p><p>In SINGLE, 833 patients were treated with dolutegravir 50&nbsp;mg film-coated tablets once daily plus fixed-dose abacavir-lamivudine (DTG + ABC/3TC) or fixed-dose efavirenz-tenofovir-emtricitabine (EFV/TDF/FTC). At baseline, median patient age was 35 years, 16% were female, 32% non-white, 7% had hepatitis C co-infection and 4% were CDC Class C, these characteristics were similar between treatment groups. Week 48 outcomes (including outcomes by key baseline covariates) are shown in Table 3.</p><p>Table 3: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic Outcomes of Randomised Treatment of SINGLE at 48 Weeks (Snapshot &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; algorithm)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>48 weeks</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DTG 50&nbsp;mg + ABC/3TC</strong></p><p><strong>once daily</strong></p><p><strong>N=414</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>EFV/TDF/FTC</strong></p><p><strong>once daily</strong></p><p><strong>N=419</strong></p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50 copies/mL</strong></p></td><td style="vertical-align:top"><p>88%</p></td><td colspan="2" style="vertical-align:top"><p>81%</p></td></tr><tr><td><p><strong>&nbsp; Treatment </strong><strong>Difference</strong>*</p></td><td colspan="3" style="vertical-align:top"><p>7.4% (95% CI: 2.5%, 12.3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non response&dagger; </strong></p></td><td style="vertical-align:top"><p>5%</p></td><td colspan="2" style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p><strong>No virologic data at Weeks 48 window </strong></p></td><td><p>7%</p></td><td colspan="2"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study/study medicinal product due to adverse event or death&Dagger;</p></td><td><p>2%</p></td><td colspan="2"><p>10%</p></td></tr><tr><td><p>Discontinued study/study medicinal product for other reasons&sect;</p></td><td><p>5%</p></td><td colspan="2"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td><p>0</p></td><td colspan="2"><p>&lt;1%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>HIV-1 RNA &lt;50 copies/mL by baseline covariates</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline Plasma Viral Load (copies/mL)</strong></p></td><td><p>n / N (%)</p></td><td colspan="2"><p>n / N (%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &pound;100,000</p></td><td><p>253 / 280 (90%)</p></td><td><p>238 / 288 (83%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &gt;100,000</p></td><td><p>111 / 134 (83%)</p></td><td><p>100 / 131 (76%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline CD4+ (cells/ mm<sup>3</sup>)</strong></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &lt;200</p></td><td style="vertical-align:top"><p>45 / 57 (79%)</p></td><td style="vertical-align:top"><p>48 / 62 (77%)</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; 200 to &lt;350</p></td><td style="vertical-align:top"><p>143 / 163 (88%)</p></td><td style="vertical-align:top"><p>126 / 159 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &sup3;350</p></td><td style="vertical-align:top"><p>176 / 194 (91%)</p></td><td style="vertical-align:top"><p>164 / 198 (83%)</p></td></tr><tr><td><p><strong>Gender</strong></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; Male</p></td><td><p>307 / 347 (88%)</p></td><td><p>291 / 356 (82%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; Female</p></td><td><p>57 / 67 (85%)</p></td><td><p>47 / 63 (75%)</p></td></tr><tr><td><p><strong>Race </strong></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; White</p></td><td><p>255 / 284 (90%)</p></td><td><p>238 /285 (84%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; African American/African&nbsp;</p><p>&nbsp; Heritage/Other</p></td><td><p>109 / 130 (84%)</p></td><td><p>99 / 133 (74%)</p></td></tr><tr><td><p><strong>Age (years)</strong></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &lt;50</p></td><td><p>319 / 361 (88%)</p></td><td><p>302 / 375 (81%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &sup3;50</p></td><td><p>45 / 53 (85%)</p></td><td><p>36 / 44 (82%)</p></td></tr><tr><td colspan="4"><p>* Adjusted for baseline stratification factors.</p><p>&dagger; Includes subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are &sup3;50 copies in the 48-week window.</p><p>&Dagger; Includes subjects who discontinued due to an adverse event or death at any time point from</p><p>Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.</p><p>&sect; Includes reasons such as withdrew consent, loss to follow-up, moved, protocol deviation.</p><p>Notes: ABC/3TC = abacavir 600&nbsp;mg, lamivudine 300&nbsp;mg in the form of Kivexa/Epzicom fixed dose combination (FDC)</p><p>EFV/TDF/FTC = efavirenz 600&nbsp;mg, tenofovir disoproxil 245&nbsp;mg, emtricitabine 200&nbsp;mg in the form of Atripla FDC.</p></td></tr></tbody></table><p>In the primary 48 weeks analysis, the proportion of patients with virologic suppression in the dolutegravir + ABC/3TC arm, was superior to the EFV/TDF/FTC arm, p=0.003, the same treatment difference was observed in subjects defined by baseline HIV RNA level (&lt; or &gt; 100,000 copies/mL). The median time to viral suppression was shorter with ABC/3TC + DTG (28 vs 84 days, p&lt;0.0001). The adjusted mean change in CD4+ T cell count from baseline were 267&nbsp;cells versus 208 cells/mm<sup>3</sup>, respectively (p&lt;0.001). Both the time to viral suppression and change from baseline analyses were pre-specified and adjusted for multiplicity. At 96 weeks, the response was 80% vs 72%, respectively. The difference in the endpoint remained statistically significant (p=0.006).&nbsp; The statistically higher responses on DTG+ABC/3TC were driven by a higher rate of withdrawals due to AEs in the EFV/TDF/FTC arm, irrespective of viral load strata. Overall treatment differences at Week 96 are applicable to patients with high and low Baseline viral loads. At 144 weeks in the open-label phase of SINGLE, virologic suppression was maintained, the DTG +ABC/3TC arm (71%) was superior to the EFV/TDF/FTC arm (63%), treatment difference was 8.3% (2.0, 14.6).</p><p>In SPRING-2, 822 patients were treated with either dolutegravir 50 mg film-coated tablets once daily or raltegravir 400 mg twice daily (blinded), both with fixed-dose ABC/3TC (around 40%) or TDF/FTC (around 60%), given open label. Baseline demographics and outcomes are summarised in Table 4.&nbsp; Dolutegravir was non-inferior to raltegravir, including within the subset of patients with the abacavir/lamivudine background regimen.</p><p>Table 4:&nbsp; Demographics and virologic outcomes of randomised treatment of SPRING-2 (snapshot algorithm)</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DTG 50&nbsp;mg</strong></p><p><strong>once daily</strong></p><p><strong>+ 2 NRTI </strong></p><p><strong>N=411</strong></p></td><td style="vertical-align:top"><p><strong>RAL 400mg</strong></p><p><strong>&nbsp;twice daily</strong></p><p><strong>+ 2 NRTI</strong></p><p><strong>N=411</strong></p></td></tr><tr><td colspan="3"><p><strong>Demographics</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Median Age (years)</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>35</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Female</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Non-white</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Hepatitis B and/or C</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>11%</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; CDC class C</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; ABC/3TC backbone</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>40%</p></td></tr><tr><td colspan="3"><p><strong>Week 48 efficacy results</strong></p></td></tr><tr><td><p>HIV-1 RNA &lt;50 copies/mL</p></td><td style="vertical-align:top"><p>88%</p></td><td style="vertical-align:top"><p>85%</p></td></tr><tr><td><p>Treatment difference*</p></td><td colspan="2" style="vertical-align:top"><p>2.5% (95% CI: -2.2%, 7.1%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Virologic non response&dagger;</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; No virologic data at Weeks 48 window</p></td><td><p>7%</p></td><td><p>7%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study/study &nbsp;medicinal product due to adverse event or death&Dagger;</p></td><td><p>2%</p></td><td><p>1%</p></td></tr><tr><td><p>Discontinued study/study &nbsp;medicinal product for other reasons&sect;</p></td><td><p>5%</p></td><td><p>6%</p></td></tr><tr><td><p>HIV-1 RNA &lt;50 copies/mL for those on ABC/3TC</p></td><td><p>86%</p></td><td><p>87%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 96 efficacy results</strong></p></td></tr><tr><td><p>HIV-1 RNA &lt;50 copies/mL</p></td><td><p>81%</p></td><td><p>76%</p></td></tr><tr><td><p>Treatment difference*</p></td><td colspan="2"><p>4.5% (95% CI: -1.1%, 10.0%)</p></td></tr><tr><td><p><strong>&nbsp; </strong>HIV-1 RNA &lt;50 copies/mL for those on ABC/3TC</p></td><td><p>74%</p></td><td><p>76%</p></td></tr><tr><td colspan="3"><p>* Adjusted for baseline stratification factors.</p><p>&dagger; Includes subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are &sup3; 50 copies in the 48-week window.</p><p>&Dagger; Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.</p><p>&sect; Includes reasons such as protocol deviation, lost to follow up, and withdrew consent.</p><p>Notes: DTG = dolutegravir, RAL = raltegravir.</p></td></tr></tbody></table><p>&nbsp;</p><p>In FLAMINGO, 485 patients were treated with dolutegravir 50 mg film-coated tablets once daily or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily, both with ABC/3TC (around 33%) or TDF/FTC (around 67%). All treatments were given open label.&nbsp; Main demographics and outcomes are summarised in Table 5.</p><p>Table 5:&nbsp; Demographics and Week 48 virologic outcomes of randomised treatment of FLAMINGO (snapshot algorithm)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DTG 50&nbsp;mg </strong></p><p><strong>once daily</strong></p><p><strong>&nbsp;+ 2 NRTI</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=242</strong></p></td><td style="vertical-align:top"><p><strong>DRV+RTV</strong></p><p><strong>800mg + 100mg</strong></p><p><strong>once daily</strong></p><p><strong>+2 NRTI</strong></p><p><strong>N=242</strong></p></td></tr><tr><td><p><strong>Demographics</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; Median Age (years)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>34</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; Female</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>17%</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; Non-white</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis B and/or C</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; CDC class C</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;&nbsp;&nbsp;&nbsp; ABC/3TC backbone</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>33%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Week 48 Efficacy Results</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>HIV-1 RNA &lt;50 copies/mL</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>83%</p></td></tr><tr><td><p>Treatment Difference*</p></td><td colspan="2" style="vertical-align:top"><p>7.1% (95% CI: 0.9%, 13.2%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic non response&dagger;</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>7%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No virologic data at Weeks 48 window</p></td><td><p>4%</p></td><td><p>10%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study/study medicinal product due to adverse event or death&Dagger;</p></td><td><p>1%</p></td><td><p>4%</p></td></tr><tr><td><p>Discontinued study/study medicinal product for other reasons&sect;</p></td><td><p>2%</p></td><td><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td><p>&lt;1%</p></td><td><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt;50copies/mL for those on ABC/3TC</p></td><td><p>90%</p></td><td><p>85%</p></td></tr><tr><td style="vertical-align:top"><p>Median time to viral suppression**</p></td><td><p>28 days</p></td><td><p>85 days</p></td></tr><tr><td colspan="3"><p>* Adjusted for baseline stratification factors, p=0.025.</p><p>&dagger; Includes subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are &sup3; 50 copies in the 48-week window.</p><p>&Dagger; Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.</p><p>&sect; Includes reasons such as withdrew consent, loss to follow-up, protocol deviation.</p><p>** p&lt;0.001.</p><p>Notes: DRV+RTV = darunavir + ritonavir, DTG = dolutegravir.</p></td></tr></tbody></table><p>At 96 weeks, virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%), (adjusted treatment difference [DTG-(DRV+RTV)]: 12.4%; 95% CI: [4.7, 20.2]). Response rates at 96 weeks were 82% for DTG+ABC/3TC and 75% for DRV/r+ABC/3TC.</p><p>In ARIA (ING117172), a randomised, open-label, active-controlled, multicenter , parallel group, non-inferiority study; 499 HIV-1 infected ART na&iuml;ve adult women were randomised 1:1 to receive either; DTG/ABC/3TC FDC film-coated tablets 50 mg/600 mg/300 mg; or atazanavir 300 mg plus ritonavir 100 mg plus tenofovir disproxil / emtricitabine 245 mg/200 mg (ATV+RTV+TDF/FTC FDC), all administered once daily.<strong><em> </em></strong></p><p>Table 6: Demographics and Week 48 virologic outcomes of randomised treatment of ARIA</p><p>(snapshot algorithm)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DTG/ABC/3TC<br />FDC<br />N=248</strong></p></td><td style="vertical-align:top"><p><strong>ATV+RTV+TDF/FTC FDC</strong></p><p><strong>N=247</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Demographics</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median Age (years)</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>37</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Female</p></td><td style="vertical-align:top"><p>100 %</p></td><td style="vertical-align:top"><p>100 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Non-white</p></td><td style="vertical-align:top"><p>54 %</p></td><td style="vertical-align:top"><p>57 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Hepatitis B and/ or C</p></td><td style="vertical-align:top"><p>6 %</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;CDC class C</p></td><td style="vertical-align:top"><p>4 %</p></td><td style="vertical-align:top"><p>4 %</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Week 48 Efficacy Results</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;HIV-1 RNA &lt;50 copies/mL</p></td><td style="vertical-align:top"><p>82 %</p></td><td style="vertical-align:top"><p>71 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>10.5 (3.1% to 17.8%) [p=0.005].</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Virologic Failure</p></td><td style="vertical-align:top"><p>6 %</p></td><td style="vertical-align:top"><p>14 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Reasons</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Data in window not below 50&nbsp;c/mL threshold</p></td><td style="vertical-align:top"><p>2 %</p></td><td style="vertical-align:top"><p>6 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Discontinued for lack of efficacy</p></td><td style="vertical-align:top"><p>2 %</p></td><td style="vertical-align:top"><p>&lt;1 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Discontinued for other reason while not below threshold</p></td><td style="vertical-align:top"><p>3 %</p></td><td style="vertical-align:top"><p>7 %</p></td></tr><tr><td style="vertical-align:top"><p>No Virologic Data</p></td><td style="vertical-align:top"><p>12 %</p></td><td style="vertical-align:top"><p>15 %</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued due to AE or death</p></td><td style="vertical-align:top"><p>4 %</p></td><td style="vertical-align:top"><p>7 %</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued for other reasons</p></td><td style="vertical-align:top"><p>6 %</p></td><td style="vertical-align:top"><p>6 %</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td style="vertical-align:top"><p>2 %</p></td><td style="vertical-align:top"><p>2 %</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>AE = Adverse event.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HIV‑1&nbsp;-&nbsp;human immunodeficiency virus type 1</p><p>DTG/ABC/3TC FDC - abacavir/dolutegravir/lamivudine fixed-dose combination</p><p>ATV+RTV+TDF/FTC FDC -atazanavir plus ritonavir plus tenofovir disproxil/emtricitabine fixed-dose combination</p></td></tr></tbody></table><p>STRIIVING (201147) is a 48-week, randomised, open-label, active controlled, &nbsp;multicenter, non-inferiority study in patients without any prior treatment failure, and without any documented resistance to any class. Virologically suppressed (HIV-1 RNA &lt;50 c/mL) subjects were randomly assigned (1:1) to continue their current ART regimen (2 NRTIs plus either a PI, NNRTI, or INI), or switch to ABC/DTG/3TC FDC film-coated tablets once daily (Early Switch). Hepatitis B co-infection was the one of main exclusion criteria.</p><p>Patients were mainly white (66%) or black (28%) of male sex (87%). Main prior transmission routes were homosexual (73%) or heterosexual (29%) contact. The proportion with a positive HCV serology was 7%. The median time from first starting ART was around 4.5 years.</p><p>Table 7: Outcomes of randomised treatment of STRIIVING (snapshot algorithm)</p><table border="1" cellspacing="0" cellpadding="0" style="width:106%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Study Outcomes (Plasma HIV-1 RNA &lt;50&nbsp;c/mL) at Week&nbsp;24 and Week&nbsp;48 &ndash; Snapshot Analysis (ITT-E Population)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>ABC/DTG/3TC<br />FDC<br />N=275<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Current ART<br /><br />N=278<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Early Switch</strong><br /><strong>ABC/DTG/3TC</strong><strong> FDC<br />N=275<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Late Switch</strong><br /><strong>ABC/DTG/3TC</strong><strong> FDC<br />N=244<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Outcome Time Point</strong></p></td><td style="vertical-align:top"><p><strong>Day 1 to W 24</strong></p></td><td style="vertical-align:top"><p><strong>Day 1 to W 24</strong></p></td><td style="vertical-align:top"><p><strong>Day 1 to W48</strong></p></td><td style="vertical-align:top"><p><strong>W24 to W48</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic Success</strong></p></td><td style="vertical-align:top"><p>85 %</p></td><td style="vertical-align:top"><p>88 %</p></td><td style="vertical-align:top"><p>83 %</p></td><td style="vertical-align:top"><p>92 %</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic Failure</strong></p></td><td style="vertical-align:top"><p>1 %</p></td><td style="vertical-align:top"><p>1 %</p></td><td style="vertical-align:top"><p>&lt;1 %</p></td><td style="vertical-align:top"><p>1 %</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; <u>Reasons</u></p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Data in window not below threshold</p></td><td style="vertical-align:top"><p>1 %</p></td><td style="vertical-align:top"><p>1 %</p></td><td style="vertical-align:top"><p>&lt;1 %</p></td><td style="vertical-align:top"><p>1 %</p></td></tr><tr><td style="vertical-align:top"><p><strong>No Virologic Data</strong></p></td><td style="vertical-align:top"><p>14 %</p></td><td style="vertical-align:top"><p>10 %</p></td><td style="vertical-align:top"><p>17 %</p></td><td style="vertical-align:top"><p>7 %</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued due to AE or death</p></td><td style="vertical-align:top"><p>4 %</p></td><td style="vertical-align:top"><p>0 %</p></td><td style="vertical-align:top"><p>4 %</p></td><td style="vertical-align:top"><p>2 %</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued for other reasons</p></td><td style="vertical-align:top"><p>9 %</p></td><td style="vertical-align:top"><p>10 %</p></td><td style="vertical-align:top"><p>12 %</p></td><td style="vertical-align:top"><p>3 %</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td style="vertical-align:top"><p>1 %</p></td><td style="vertical-align:top"><p>&lt;1 %</p></td><td style="vertical-align:top"><p>2 %</p></td><td style="vertical-align:top"><p>2 %</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>ABC/DTG/3TC FDC = abacavir/dolutegravir/lamivudine fixed-dose combination; AE = adverse event; ART&nbsp;=&nbsp;antiretroviral therapy; HIV‑1&nbsp;=&nbsp;human immunodeficiency virus type 1; ITT‑E&nbsp;=&nbsp;intent‑to-treat exposed; W&nbsp;=&nbsp;week.</p></td></tr></tbody></table><p>Virologic suppression (HIV-1 RNA &lt;50 copies/mL) in the ABC/DTG/3TC FDC group (85%) was statistically non-inferior to the current ART groups (88%) at 24 weeks. The adjusted difference in proportion and 95% CI [ABC/DTG/3TC vs current ART] were 3.4%; 95% CI: [-9.1, 2.4]. After 24 weeks all remaining subjects switched to ABC/DTG/3TC FDC (Late Switch). Similar levels of virologic suppression were maintained in both the Early and Late Switch groups at 48 weeks.</p><p>&nbsp;</p><p><em><u>De novo</u></em><u> resistance in patients failing therapy in SINGLE, SPRING-2 and FLAMINGO</u></p><p><em>De novo</em> resistance was not detected to the integrase class or the NRTI class in any patients who were treated with dolutegravir + abacavir/lamivudine in the three studies mentioned.&nbsp;</p><p>For the comparators typical resistance was detected with TDF/FTC/EFV (SINGLE; six with NNRTI associated resistance and one with major NRTI resistance) and with 2 NRTIs + raltegravir (SPRING-2; four with major NRTI resistance and one with raltegravir resistance), while no <em>de novo</em> resistance was detected in patients treated with 2 NRTIs + DRV/RTV (FLAMINGO).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In a Phase I/II 48 week multicenter , open-label study (P1093/ING112578), the pharmacokinetic parameters, safety, tolerability and efficacy of dolutegravir was evaluated in combination regimens in HIV-1 infected infants, children and adolescents.</p><p>At 24 weeks, 16 of 23 (69%) adolescents (12 to 17 years of age) treated with dolutegravir once daily (35&nbsp;mg n=4; 50&nbsp;mg n=19) plus OBR achieved viral load less than 50 copies/mL.</p><p>Twenty out of 23 children and adolescents (87%) had &gt;1 log<sub>10 </sub>c/mL decrease from Baseline in HIV-1 RNA or HIV-1 RNA &lt;400 c/mL at Week 24. Four subjects had virologic failure none of which had INI resistance at the time of virologic failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Triumeq film-coated tablet has been shown to be bioequivalent to dolutegravir single entity film-coated tablet and abacavir/lamivudine fixed-dose combination tablet (ABC/3TC FDC) administered separately. This was demonstrated in a single dose, 2-way crossover bioequivalence study of Triumeq (fasted) versus 1 x 50 mg dolutegravir tablet, plus 1 x 600mg abacavir/300 mg lamivudine tablet (fasted) in healthy subjects (n=66)..</p><p>The pharmacokinetic properties of dolutegravir, lamivudine and abacavir are described below.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b27e1dc7-a30a-4b47-98b0-2388c826dccd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><u>Absorption</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_05dfd23d-c071-4688-8421-6a4f6b5a37c1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Dolutegravir, abacavir and lamivudine are rapidly absorbed following oral administration. The absolute bioavailability of dolutegravir has not been established. The absolute bioavailability of oral abacavir and lamivudine in adults is about 83% and 80-85% respectively. The mean time to maximal serum concentrations (t<sub>max</sub>) is about 2 to 3 hours (post dose for tablet formulation), 1.5&nbsp;hours and 1.0&nbsp;hour for dolutegravir, abacavir and lamivudine, respectively.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2c125211-9ef5-48eb-a754-76902e08e93e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Exposure to dolutegravir was generally similar between healthy subjects and HIV‑1&ndash;infected subjects. In HIV‑1&ndash;infected adult subjects following dolutegravir 50&nbsp;mg film-coated tablets once daily, the steady-state pharmacokinetic parameters (geometric mean [%CV]) based on population pharmacokinetic analyses were AUC<sub>(0-24)</sub>&nbsp;=&nbsp;53.6 (27)&nbsp;mg.h/mL, C<sub>max</sub>&nbsp;=&nbsp;3.67 (20)&nbsp;mg/mL, and C<sub>min</sub>&nbsp;=&nbsp;1.11 (46)&nbsp;mg/mL. Following a single dose of 600&nbsp;mg of abacavir, the mean (CV) C<sub>max</sub> is 4.26&nbsp;&micro;g/ml (28%) and the mean (CV) AUC<sub>&yen;</sub><sub> </sub>is 11.95&nbsp;&micro;g.h/ml (21%). Following multiple-dose oral administration of lamivudine 300&nbsp;mg once daily for seven days, the mean (CV) steady-state C<sub>max</sub> is 2.04&nbsp;&micro;g/ml (26%) and the mean (CV) AUC<sub>24</sub> is 8.87&nbsp;&micro;g.h/ml (21%).</p><p>The effect of a high fat meal on Triumeq film-coated tablet was evaluated in a subgroup of subjects (n=12) of the single dose, 2-way crossover bioequivalence study.</p><p>Plasma C<sub>max</sub> and AUC of dolutegravir following administration of Triumeq film-coated tablet with a high fat meal were 37% and 48% higher, respectively, than those following administration of Triumeq film-coated tablet in the fasted state). For abacavir there was a decrease in C<sub>max</sub> with 23% and AUC was unchanged. The exposure of lamivudine was similar with and without food. These results indicate that Triumeq film-coated tablet can be taken with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution of dolutegravir (following oral administration of suspension formulation, Vd/F) is estimated at 12.5&nbsp;L.&nbsp; Intravenous studies with abacavir and lamivudine showed that the mean apparent volume of distribution is 0.8 and 1.3&nbsp;l/kg respectively.</p><p>Dolutegravir is highly bound (&gt; 99%) to human plasma proteins based on <em>in vitro</em> data.&nbsp; Binding of dolutegravir to plasma proteins is independent of dolutegravir concentration.&nbsp; Total blood and plasma drug-related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components. The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (&lt;35 g/L) as seen in subjects with moderate hepatic impairment. Plasma protein binding studies <em>in vitro</em> indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding <em>in vitro</em> (&lt;&nbsp;36%).</p><p>Dolutegravir, abacavir and lamivudine are present in cerebrospinal fluid (CSF).&nbsp;</p><p>In 13 treatment-na&iuml;ve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18&nbsp;ng/mL (comparable to unbound plasma concentration, and above the IC50). Studies with abacavir demonstrate a CSF to plasma AUC ratio of between 30 to 44%. The observed values of the peak concentrations are 9-fold greater than the IC50 of abacavir of 0.08&nbsp;&micro;g/ml or 0.26&nbsp;&micro;M when abacavir is given at 600&nbsp;mg twice daily<strong>. </strong>The mean ratio of CSF/serum lamivudine concentrations 2-4&nbsp;hours after oral administration was approximately 12%. The true extent of CNS penetration of lamivudine and its relationship with any clinical efficacy is unknown.</p><p>Dolutegravir is present in the female and male genital tract.&nbsp; AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state. AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.</p><p><strong>&nbsp;</strong></p><p><u>Biotransformation</u></p><p>Dolutegravir is primarily metabolised via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study).&nbsp; Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (&lt; 1% of the dose).&nbsp; Fifty-three percent of total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.&nbsp; Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).</p><p>Abacavir is primarily metabolised by the liver with approximately 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5&rsquo;-carboxylic acid and 5&rsquo;-glucuronide which account for about 66% of the administered dose. These metabolites are excreted in the urine.</p><p>Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared by renal excretion of unchanged lamivudine. The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%).</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p><em>In vitro</em>, dolutegravir demonstrated no direct, or weak inhibition (IC50&gt;50 &mu;M) of the enzymes cytochrome P<sub>450</sub> (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1 or UGT2B7, or the transporters Pgp, BCRP, BSEP, organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OCT1, MATE2-K, multidrug resistance-associated protein 2 (MRP2) or MRP4. <em>In vitro</em>, dolutegravir did not induce CYP1A2, CYP2B6 or CYP3A4. Based on this data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see section<em> Interaction with other medicinal products and other forms of interaction).&nbsp;</em></p><p><em>In vitro</em>, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1.</p><p><em>In vitro</em>, abacavir did not inhibit or induce CYP enzymes (other than CY1A1 and CYP3A4 [limited potential], see section<em> Interaction with other medicinal products and other forms of interaction).</em></p><p>and demonstrates no or weak inhibition of OATP1B1, OAT1B3, OCT1, OCT2, BCRP and P-gp or MATE2-K.&nbsp; Abacavir is therefore not expected to affect the plasma concentrations of medicinal products that are substrates of these enzymes or transporters.</p><p>Abacavir was not significantly metabolised by CYP enzymes.&nbsp; <em>In vitro</em>, abacavir was not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, MRP2 or MRP4 therefore medicinal products that modulate these transporters are not expected to affect abacavir plasma concentrations.</p><p><em>In vitro,</em> lamivudine did not inhibit or induce CYP enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and demonstrated no or weak inhibition of OATP1B1, OAT1B3, OCT3, BCRP, P-gp, MATE1 or MATE2-K.&nbsp; Lamivudine is therefore not expected to affect the plasma concentrations of medicinal products that are substrates of these enzymes or transporters.</p><p>Lamivudine was not significantly metabolised by CYP enzymes.</p><p>&nbsp;</p><p><u>Elimination</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_15e8f799-de8b-47d3-aed2-e3931bc3a28c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Dolutegravir has a terminal half-life of ~14&nbsp;hours. The apparent oral clearance (CL/F) is approximately 1 L/hr in HIV-infected patients based on a population pharmacokinetic analysis.<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:"MS Mincho"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c24e6f19-3fc9-45c6-8d54-9cbfcf2264dc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:"MS Mincho"'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>The mean half-life of abacavir is about 1.5&nbsp;hours. The geometric mean terminal half-life of intracellular active moiety carbovirtriphosphate (TP) at steady state is 20.6 hours. Following multiple oral doses of abacavir 300&nbsp;mg twice a day there is no significant accumulation of abacavir. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83% of the administered abacavir dose in the urine. The remainder is eliminated in the faeces.</p><p>The observed lamivudine half-life of elimination is 18 to 19&nbsp;hours. For patients receiving lamivudine 300 mg once daily, the terminal intracellular half-life of lamivudine-TP was 16 to 19 hours. The mean systemic clearance of lamivudine is approximately 0.32 L/h/kg, predominantly by renal clearance (&gt;&nbsp;70%) via the organic cationic transport system. Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Dose reduction is required for patients with creatinine clearance &lt;&nbsp;30&nbsp;mL/min (see section <em>&nbsp;Posology and method of administration</em>).</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s)</u><!--[if supportFields]><u><span style='mso-bidi-font-size:
11.0pt;color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f6ef9eea-f5c9-4a0c-b71a-3d7fcc36e67f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>In a randomised, dose-ranging trial, HIV‑1&ndash;infected subjects treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity with mean decline in HIV-1 RNA of 2.5&nbsp;log<sub>10</sub> at day 11 for 50 mg dose. This antiviral response was maintained for 3 to 4 days after the last dose in the 50&nbsp;mg group.</p><p>&nbsp;</p><p><u>Intracellular pharmacokinetics</u><!--[if supportFields]><u><span style='mso-bidi-font-size:
11.0pt;color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_98cf4468-baf3-43e2-91fd-7fefd32a533f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>The geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life of 2.6 hours. The terminal intracellular half-life of lamivudine-TP was prolonged to 16-19 hours, supporting once daily dosing of ABC and 3TC.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_68189c4c-c4cc-4494-be0b-c05048ce64b1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>Pharmacokinetic data has been obtained for dolutegravir, abacavir and lamivudine separately.</p><p>Dolutegravir is primarily metabolised and eliminated by the liver. A single dose of 50 mg of dolutegravir was administered to 8 subjects with moderate hepatic impairment (Child-Pugh class B) and to 8 matched healthy adult controls. While the total dolutegravir concentration in plasma was similar, a 1.5 to 2-fold increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment compared to healthy controls. No dose adjustment is considered necessary for patients with mild to moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of dolutegravir has not been studied.</p><p>Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600&nbsp;mg dose. The results showed that there was a mean increase of 1.89-fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life. No recommendation on dose reduction is possible in patients with mild hepatic impairment due to substantial variability of abacavir exposure.</p><p>Data obtained in patients with moderate to severe hepatic impairment show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.</p><p>Based on data obtained for abacavir, Triumeq is not recommended in patients with moderate or severe hepatic impairment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Pharmacokinetic data have been obtained for dolutegravir, lamivudine and abacavir separately.</p><p>Renal clearance of unchanged active substance is a minor pathway of elimination for dolutegravir. A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment (CrCL&lt;30&nbsp;mL/min). No clinically important pharmacokinetic differences between subjects with severe renal impairment (CrCL&lt;30&nbsp;mL/min) and matching healthy subjects were observed. Dolutegravir has not been studied in patients on dialysis, though differences in exposure are not expected.</p><p>Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function.</p><p>Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance.</p><p>Based on the lamivudine data, Triumeq is not recommended for patients with creatinine clearance of &lt;&nbsp;&nbsp;30 mL/min.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Elderly</u></p><p>Population pharmacokinetic analysis of dolutegravir using data form HIV-1 infected adults showed that there was no clinically relevant effect of age on dolutegravir exposure.</p><p>Pharmacokinetic data for dolutegravir, abacavir and lamivudine in subjects &gt;65 years of age are limited.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to 17&nbsp;years) showed that dolutegravir 50&nbsp;mg once daily dosage resulted in dolutegravir exposure comparable to that observed in adults who received dolutegravir 50&nbsp;mg once daily.</p><p>Limited data are available in adolescents receiving a daily dose of 600 mg of abacavir and 300 mg of lamivudine.&nbsp; Pharmacokinetic parameters are comparable to those reported in adults.</p><p>&nbsp;</p><p><u>Polymorphisms in drug metabolising enzymes</u></p><p>There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).</p><p>&nbsp;</p><p><u>Gender</u></p><p>Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of gender on the exposure of dolutegravir. There is no evidence that a dose adjustment of dolutegravir, abacavir or lamivudine would be required based on the effects of gender on PK parameters.</p><p>&nbsp;</p><p><u>Race</u></p><p>Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of race on the exposure of dolutegravir. The pharmacokinetics of dolutegravir following single dose oral administration to Japanese subjects appear similar to observed parameters in Western (US) subjects. There is no evidence that a dose adjustment of dolutegravir, abacavir or lamivudine would be required based on the effects of race on PK parameters.</p><p>&nbsp;</p><p><u>Co-infection with Hepatitis B or C</u></p><p>Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant effect on the exposure to dolutegravir. There are limited pharmacokinetic data on subjects with hepatitis B co-infection (see section <em>&nbsp;Special warnings and precautions for use</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data available on the effects of the combination of dolutegravir, abacavir and lamivudine in animals, except a negative <em>in vivo</em> rat micronucleus test which tested the effects of the combination of abacavir and lamivudine.<em><u>&nbsp; </u></em></p><p>&nbsp;</p><p><u>Mutagenicity and carcinogenicity</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_14aae6bc-9557-4dee-93fe-f76224845f66 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Dolutegravir was not mutagenic or clastogenic using <em>in vitro</em> tests in bacteria and cultured mammalian cells, and an <em>in viv</em>o rodent micronucleus assay.<!--[if supportFields]><span
style='mso-fareast-font-family:"MS Mincho"'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d9a0182f-b189-4523-b48b-3d1d7aa940c1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-fareast-font-family:"MS Mincho"'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Neither abacavir nor lamivudine were mutagenic in bacterial tests, but consistent with other nucleoside analogues, inhibit cellular DNA replication in <em>in vitro</em> mammalian tests such as the mouse lymphoma assay. The results of an <em>in vivo</em> rat micronucleus test with abacavir and lamivudine in combination were negative.</p><p>&nbsp;</p><p>Lamivudine has not shown any genotoxic activity in the <em>in vivo</em> studies. Abacavir has a weak potential to cause chromosomal damage both <em>in vitro</em> and <em>in vivo</em> at high tested concentrations.</p><p>&nbsp;</p><p>The carcinogenic potential of a combination of dolutegravir, abacavir and lamivudine has not been tested. Dolutegravir was not carcinogenic in long term studies in the mouse and rat. In long-term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential. Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and in the liver, urinary bladder, lymph nodes and the subcutis of females.</p><p>&nbsp;</p><p>The majority of these tumours occurred at the highest abacavir dose of 330&nbsp;mg/kg/day in mice and 600&nbsp;mg/kg/day in rats. The exception was the preputial gland tumour which occurred at a dose of 110&nbsp;mg/kg in mice. The systemic exposure at the no effect level in mice and rats was equivalent to 3 and 7 times the human systemic exposure during therapy. While the clinical relevance of these findings is unknown, these data suggest that a potential carcinogenic risk to humans is outweighed by the clinical benefit.</p><p>&nbsp;</p><p><u>Repeat-dose toxicity</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_c14e5d86-f210-414b-ad4a-5013ea6177b5
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></u><![endif]--></p><p>The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks).&nbsp; The primary effect of dolutegravir was gastrointestinal intolerance or irritation in rats and monkeys at doses that produce systemic exposures approximately 38 and 1.5 times the 50&nbsp;mg human clinical exposure based on AUC, respectively.&nbsp; Because gastrointestinal (GI) intolerance is considered to be due to local active substance administration, mg/kg or mg/mPP<sup>2</sup>PP metrics are appropriate determinates of safety cover for this toxicity.&nbsp; GI intolerance in monkeys occurred at 30 times the human mg/kg equivalent dose (based on 50&nbsp;kg human), and 11 times the human mg/mPP<sup>2</sup>PP equivalent dose for a total daily clinical dose of 50&nbsp;mg.&nbsp;</p><p>&nbsp;</p><p>In toxicology studies abacavir was shown to increase liver weights in rats and monkeys. The clinical relevance of this is unknown. There is no evidence from clinical studies that abacavir is hepatotoxic. Additionally, autoinduction of abacavir metabolism or induction of the metabolism of other medicinal products hepatically metabolised has not been observed in humans.</p><p>&nbsp;</p><p>Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 21 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8cbfcc57-0502-44bb-934e-5bb7bcb7ac7a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>In reproductive toxicity studies in animals, dolutegravir, lamivudine and abacavir were shown to cross the placenta.</p><p>&nbsp;</p><p>Oral administration of dolutegravir to pregnant rats at doses up to 1000&nbsp;mg/kg daily from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (50 times the 50&nbsp;mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC).</p><p>&nbsp;</p><p>Oral administration of dolutegravir to pregnant rabbits at doses up to 1000&nbsp;mg/kg daily from days 6 to 18 of gestation did not elicit developmental toxicity or teratogenicity (0.74 times the 50mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC).&nbsp; In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000&nbsp;mg/kg (0.74 times the 50&nbsp;mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC).</p><p>&nbsp;</p><p>Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A similar effect was not seen in rats even at very high systemic exposure.</p><p>&nbsp;</p><p>Abacavir demonstrated toxicity to the developing embryo and foetus in rats, but not in rabbits. These findings included decreased foetal body weight, foetal oedema, and an increase in skeletal variations/malformations, early intra-uterine deaths and still births. No conclusion can be drawn with regard to the teratogenic potential of abacavir because of this embryo-foetal toxicity.</p><p>&nbsp;</p><p>Fertility studies in rats have shown that dolutegravir, abacavir and lamivudine have no effect on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Tablet core:</u></em></p><p>D-Mannitol</p><p>Microcrystalline Cellulose</p><p>Povidone (K29/32)</p><p>Sodium Starch Glycollate</p><p>Magnesium Stearate</p><p>Purified Water</p><p><em><u>Tablet coating:</u></em></p><p>Poly (vinyl) alcohol &ndash; partially hydrolysed</p><p>Titanium dioxide</p><p>Macrogol</p><p>Talc</p><p>Iron Oxide Black</p><p>Iron Oxide Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Expiry date is indicated on the outer pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store Below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Keep the bottle tightly closed.</p><p>Do not remove the desiccant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White HDPE (high density polyethylene) bottles closed with polypropylene child-resistant closures, with a polyethylene faced induction heat seal liner. Each bottle contains 30 film-coated tablets and a desiccant.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><em>TRIUMEQ is </em>trademark owned by or licensed to ViiV Healthcare group of companies.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_04af9826-fe45-45be-83c4-3abb73fb74e1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&copy; 2024 ViiV Healthcare group of companies, all rights reserved.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_64a32f03-006e-42ce-906f-f6e0f8c38ffa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;color:black'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p style="text-align:center"><strong>OUTER PACK IS INCLUDING THE FOLLOWING ALERT CARD</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>IMPORTANT - ALERT CARD</strong></p><p style="text-align:center"><strong><em>TRIUMEQ</em> (dolutegravir/abacavir/lamivudine) tablets</strong></p><p style="text-align:center"><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><p>Since <em>TRIUMEQ </em>contains abacavir, some patients taking <em>TRIUMEQ </em>may develop a hypersensitivity reaction (serious allergic reaction) which <strong>can be life-threatening </strong>if treatment with <em>TRIUMEQ </em>is continued. <strong>CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking <em>TRIUMEQ </em>if:</strong></p><p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get a skin rash OR<!--[if supportFields]><span lang=EN-US style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_66cb38ba-2008-4894-b023-270120175392 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>you get one or more symptoms from at least TWO of the following groups</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, sore throat, or cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomiting or diarrhoea or abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe tiredness or achiness or generally ill feeling.</p><p>If you have discontinued <em>TRIUMEQ </em>due to this reaction, <strong>YOU MUST NEVER TAKE </strong><em>TRIUMEQ</em>, or any other medicine containing abacavir (<em>ZIAGEN, KIVEXA </em>or <em>TRIZIVIR</em>) again as <strong>within hours </strong>you may experience a life-threatening lowering of your blood pressure or death</p></td></tr></tbody></table><p style="text-align:center">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland

Marketing Authorization Holder 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VERSION NUMBER: UK Issue 33 Draft 1
DATE OF REVISION OF TEXT: 19 January 2024 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>